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Quorum sensing (QS) is a phenomenon in bacteria where the accumulation of 
extracellular signaling molecules (autoinducers, AIs), which enable bacterial cells to 
sense neighboring cells (population density), reaches certain threshold and triggers 
group behaviors of bacteria including virulence production and biofilm formation. The 
inhibition of QS and hence toxin production or biofilm formation by pathogenic 
bacteria has been suggested as an alternative strategy to deal with the problem of 
bacterial resistance to traditional antibiotics. Inhibiting QS will not kill bacteria, 
however the expectation is that resistance to a QS antagonist will not be as widespread 
as it is for traditional cytotoxic antibiotics.   
In Chapters 2 and 3 of this dissertation, we report the syntheses and biological 
evaluations of various analogs (C1 substituted, ester protected and 3,3-dihalogenated) 
of a universal QS signaling molecule, AI-2, which is found in both Gram-positive and 
Gram-negative bacteria. We report that modifications to the native AI-2 molecule 
affords analogs that can potently inhibit QS processes in E. coli and Salmonella.  
In Chapter 4, we explore the development of small molecule modulators of 
species-specific acylhomoserine lactone autoinducers, called AI-1. In the past three 
 
 
decades, intensive efforts have been dedicated to the development of modulators of AI-
1-based QS signaling. The majority of modulators, reported to date, have kept the 
lactone head group and modified the acyl tail. These synthetic modulators, although 
effective, are not drug-like because lactones are susceptible to chemical and enzymatic 
hydrolysis. We demonstrate that 3-aminooxazolidinone based AI-1 analogs, which are 
hydrolytically more stable than homoserine lactone-based compounds, can also 
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Chapter 1. Introduction 
 
1.1 A bacteria battle and a post-antibiotic era. 
The fight against pathogenic bacteria has been ongoing since the beginning of 
human existence. Until the 1950s, when many antibiotics were discovered or 
developed, death from bacterial infections was common and many epidemics or 
pandemics occurred. For example, in the fourteenth century, more than one third of the 
population in Europe was killed by the Black Death epidemic, caused by Yersinia 
pestis. In the pre-antibiotic era, about 30% of all deaths were related to bacterial 
infection in the United States. In the present day, bacterial infection is still a common 
problem and new treatments continue to be developed.  
The first commercially available antibiotic was sulfamide protonsil. However, 
it was the discovery by Sir Alexander Fleming in 1928 that ushered in a new era of 
antibacterial therapeutics. Fleming discovered that a Penicillium fungus produced an 
antibacterial substance that could kill bacteria. Following the golden age of antibiotic 
discovery, between 1940 and 1960, it was then discovered that bacteria have 
sophisticated mechanisms to develop resistance to antibiotics (Figure 1-1 summarizes 
the timeline of antibiotic discovery or development and emergence of resistant bacterial 
strain in the clinic1). During the past few decades, scientists have continued to develop 
new classes of antibiotics, as well as introduce successive generations of the existing 
drug classes that could increase spectrum activity and improve pharmacokinetics in 
order to replace the old antibiotics, which continue to be rendered ineffective due to 
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bacterial resistance (Table 1-1). There is however no reason to believe that new 
antibacterial agents will not face the same resistance issues and it appears that mankind 
will always have a never ending battle with bacteria. Currently, methicillin- and 
vancomycin-resistant Staphylococcus aureus (MRSA and VRSA), vancomycin-
resistant Enterococcus (VRE), penicillin-resistant Streptococcus pneumonia (PRSP), 
multi-drug resistant (MDR) Clostridium difficile put enormous stress on global 
healthcare. It has been estimated that 20% of the global population are persistent 
carriers of S. aureus;2 and about nineteen thousand deaths in the US are due to MRSA3. 





Figure 1-1. Timeline showing the deployment of representative antibiotics and resistance observed (summarized from literatures1). 
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synthesis 
Table 1-1. Successive generations of representative antibiotic classes and their primary targets. Core scaffolds are highlighted in blue while peripheral 
chemical modifications (R groups) are in black. Most antibiotics on the market inhibit five major targets in bacteria (also see Figure 1-2).
6 
 
There are multiple factors that lead to the origin of bacterial resistance to 
antibiotics. Historically, more than 60% of existing antibiotics and their semi-synthetic 
derivatives are derived from or inspired by natural products,4 and many of them were 
discovered by systematic screening methods of soil bacteria Streptomyces. This method 
was introduced by Ukrainian-American microbiologist Selman Waksman in the 1940s. 
Antibiotic producing bacteria have co-existed with other bacteria for billions of years 
and so it is not surprising that resistance to these molecules evolved before they were 
discovered by man. Recently, Wright and colleagues identified diverse homologues of 
known antibiotic resistance genes from 30,000-year-old permafrost sediments, 
supporting the argument that these resistance genes evolved before man started using 
antibiotics on an industrial scale.5 Antibiotic resistance genes can be disseminated 
vertically and horizontally throughout microbial communities.6 As a result, it is not 
surprising that most soil-dwelling bacteria show some form of antibiotic resistance.7  
Although antibiotic resistance genes and the spread of these genes occur 
naturally without man’s intervention, modern activities have exacerbated the antibiotic 
resistance problem. It is believed that the widespread prescription of antibiotics to 
patients, excessive use of antibiotics in animal husbandry and non-therapeutic use of 
antibiotics, for example as prophylatics in household products, have put evolutionary 
pressure on bacteria to develop resistance.8 
Bacteria use several pathways to render the antibiotics ineffective: 1. 
Overexpression of enzymes that can modify the antibiotics, rendering them inactive; 2. 
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Mutation of the bacterial target site, which blocks the binding of antibiotics to the target 
site; 3. Export of antibiotics to extracellular media or loss of porin channels, resulting 
in lower permeability of antibiotics.9  
The rate of new antibiotic discovery is much slower than the rate of resistance 
development, and the additional decreased pharmaceutical investment is worrisome.10 
Because developing new drugs against existing bacterial targets could lead to cross 




Figure 1-2. Major targets for antibacterial action. a) Inhibition of cell wall synthesis. 
b) Inhibition of protein synthesis. c) Inhibition of DNA or RNA synthesis. d) Inhibition 




In 2010, the Infectious Diseases Society of America (IDSA) proposed the 10 x 
'20 Initiative, that calls for 10 new systematic antibiotics by 2020.12 In 2011, the US 
government issued $94 million of funding to support the search for chemically diverse 
novel antibiotic candidates. Policies and incentives have been made to favor antibiotic 
R&D, as well. This year, 2014, World Health Organization (WHO) published 
“Antimicrobial resistance: global report on surveillance 2014” to raise public 
awareness.13 Lastly, the academic society has also been advocating a paradigm shift in 
antibiotic discovery, by targeting processes in bacteria that cause disease rather than 
killing bacetria, which creates evolutionary pressures for resistance to emerge. 
Examples of processes to target in bacteria include toxin production and biofilm 
formation, both of which are partly regulated by bacterial cell-to-cell communication 




1.2 Quorum sensing inhibition—a new strategy to fight bacteria 
(Part of this section was published in reference 14.) 
Since antibiotics ultimately put evolutionary pressure on pathogens to develop 
resistance, a new strategy to treat bacterial infections, which does not necessarily kill 
bacteria but rather curbs the virulence and biofilm formation (an aggregate of bacterial 
cells, extracellular DNA, proteins and polysaccharides, to some extent enhances 
bacterial tolerance to antibiotics15), has been proposed.1b, 9 It has been shown that 
quorum sensing (QS, Figure 1-3), a system bacteria use to communicate and respond 
as a collective to population density, but not critical to individual vitality, plays a critical 
role in regulating virulence and formation of biofilm.16 In 1965, a hormone-like cell 
product was discovered in S. pneumonia17 and was later identified as an autoinducing 
peptide.18 The term quorum sensing was first implicitly defined by Nealson and co-
workers in 1970, to describe the production of light by V. fischeri at high cell densities 
(i.e., a population-dependent process).19 Nealson and co-workers then postulated that 
the bioluminescence from V. fischeri was regulated by molecules, called “autoinducers 
(AIs)”. Subsequently, several autoinducers (both intraspecies and interspecies) have 











Figure 1-3. a) Increased concentration of autoinducers in bacterial biofilms promotes 
the synthesis of biofilm matrices, such as adhesion proteins and polysaccharides, which 
are required for the maintenance of the biofilm structure; b) Autoinducers repress the 
production of virulence factors as well as the synthesis of the components of the 
bacterial secretory system, such as T3SS, in some bacteria (for example,  AI-1, AI-2 
and CAI-1 represses T3SS gene expression in V. harveyi20). 
 
Because autoinducers (AIs) are the signaling molecules in QS, a useful strategy 
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to inhibit QS and hence reduce toxin production and biofilm formation in some bacteria 
is to use antagonists of autoinducers. It is however worth mentioning that bacterial 
toxin production and biofilm formation could also be regulated by pathways other than 
QS, so anti-QS agents should not be considered as the only method for reducing all 
toxin production and biofilm formation. There are three major classes of autoinducers 
(Figure 1-4): AI-1 (or N-Acyl homoserin lactones, AHLs, 1-23),21 oligopeptides/AIP 
(autoinducing peptide, 1-24)18, 22 and AI-2(1-25)23. There are also other bacterial 
signaling molecules that do not fall under the above three classes, such as PQS (P. 
pseudomonas quinolone signal, 1-26)24, γ-butyrolactone(1-27)25, CAI-1(1-28)26, DSF 
(diffusible signal factor, 1-29)27, 2-AA (2-amino acetophenone, 1-30)28, DKP 
(diketopiperazine,  1-31)29,  IQS (1-32)30 and CSP (competence stimulating peptide, 
1-33)31. It is worth noting that AI-2 (1-25) exists as a collection of equilibrium mixtures. 
Starting with its linear form DPD (1-25a), the hydroxyl group at C5 position tends to 
attack the carbonyl group at C2 position and cyclize as a hydrofuranone, which goes 
through hydrolysis and tautomerization. 
Due to the pivotal role played by quorum sensing in bacterial pathogenesis 
(virulence expression) and resistance (biofilm formation), quorum sensing receptors 
have emerged as potential targets for anti-infective therapy. In the last two decades, 
attempts have been made to find or develop inhibitors for different receptors, which are 
involved in the production and perception/response to autoinducers chiefly on AI-1 and 
AI-2. There are several established cell models and assays that aid the studies of 
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quorum sensing and herein a few representatives will be showcased. 
Figure 1-4. Structures of Autoinducer molecules. AI-2 is a term used to described DPD 
(4,5-Dihydroxy-2,3- pentanedione, 1-25a) and isomers in equilibrium. 
 
The quorum sensing systems in Vibrios have been well studied.32 In V. harveyi, 
three QS systems mediated by three different autoinducers have been characterized 
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(Figure 1-5).33 Whereas HAI-1 (1-26) is only found in V. harveyi,34 CAI-1 (1-28) is 
found to be active in other Vibrios.35 AI-2 is found in more than 70 bacterial species as 
a non-specific interspecies signaling molecule,36 and the active form of AI-2 in V. 
harveyi is its borate form 1-25d. CAI-1, HAI-1 and AI-2 are sensed by CqsS, LuxN 
and LuxQ, respectively. LuxQ associates with LuxP, a periplasmic binding protein, to 
form LuxPQ and regulate phosphorylation signal transduction cascade.37 At low cell 
density, as well as low AI concentration, these sensors acts as kinases and transfer 
phosphate to LuxU, which then relays a phosphate group to LuxO. LuxO-phosphate (a 
transcriptional activator), along with sigma factor σ54, activates the expression of 
regulatory small RNAs (sRNAs) Qrr1-5.38 Qrr1-5, in conjunction with the chaperone 
Hfq, destabilizes the luxR mRNA so that LuxR synthesis is suppressed. Qrr1-5, in 
conjunction with the chaperone Hfq, destabilizes the luxR mRNA so that LuxR 
synthesis is suppressed. At high AI concentration, the sensors become phosphatases, 
which dephosphorylate LuxU, which in turn also dephosphorylates LuxO. 
Dephosphorylated LuxO is no longer active and therefore, the concentrations of Qrr1-
5, which degrade the mRNA of LuxR, decrease. As the concentration of LuxR, which 
is a transcription factor, increases, the genes that are controlled by LuxR (some of 
which are virulence determinants) are expressed. In V. cholerae, sRNAs Qrr1-4 






Figure 1-5. V. harveyi quorum sensing system. Arrows denote the phosphorelay at low 
cell density. 
 
Apart from the characterized AI-2 system in Vibrios, AI-2 signaling in enteric 
bacteria has also been well characterized. S. typhimurium and E. coli share a similar 
QS system (Figure 1-6). In these bacteria, the cyclic form of AI-2, R-THMF 1-25f, is 
recognized by periplasmic binding protein LsrB.39 Once AI-2 is internalized via LsrB, 
part of the Lsr transporter encoded by lsrACDB operon, it is phosphorylated by a kinase, 
LsrK, and the phospho-AI-2 then binds to the repressor LsrR to de-repress the lsr 
operon.40 LsrF and LsrG can further process phospho-AI-2 and yield 
dihydroxyacetonephosphate (DHPA, 1-27) and acetyl-CoA, two key metabolites.41 
When AI-2 concentration is low and hence, the concentration of phospho-AI-2 is also 
low, LsrR binds the lsr promoter to inhibit the transcription or lsr genes whereas at high 
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AI-2 concentration, lsr genes are transcribed due to the de-repression of LsrR. Both 
LsrK and LsrR play key regulatory roles in the biofilm formation of E. coli.42 It has 
been shown that the deletion of lsrR affects the expression of 146 genes whereas 
deleting lsrK affected 149 genes.42a Interestingly, S. typhimurium and E. coli do not 
produce AHLs, but they can detect AHLs synthesized by other Gram-negative bacteria 
via SdiA, a homologue of LuxR.43 So far, little is known about the genes that SdiA 
regulate.44 
 





1.3 AI-2 signaling in other bacteria and inhibitors of AI-2 signaling 
As already stated, AI-2 is found in many bacteria and with the exception of 
enteric bacteria and Vibrios, remain poorly characterized in other bacterial species. 
Table 1-2 lists the different bacteria that have been shown to respond to AI-2 and details 
some bacterial phenotypes that are regulated by the AI-2/LuxS QS system 
In the last decade, attempts have been made to find or develop inhibitors for 
different receptors (Figure 1-7), which are involved in the production and 
perception/response to AI-2. There are a few crystal structures of receptor/AI-2 
complexes that have been solved. These structures provide important insights for the 
medicinal chemist to develop anti-AI-2 small molecules. The structures could also be 
used for docking experiments to determine in silico which small molecules are viable 
candidates to develop into QS antagonists. 
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Strain LuxS type 
synthase 
AI-2 Receptor Functions regulated by AI-2 Diseases References 
Actinobacillus 
actinomycetemcomitans 
LuxS RbsB,a LsrBa Optimal growth under iron starvation and biofilm 
development 
Associated with localized aggressive periodontitis 45,46 
Actinobacillus 
pleuropneumoniae 
LuxS unknown Pleiotropic effects on biofilm formation, adhesion 
ability, and iron metabolism. LuxS is essential for 
the survival in natural host 
Respiratory pathogen found in pigs 47 
Bacillus anthracis LuxS unknow Virulence gene expression, cell growth Etiological agent of anthrax in livestock 48 
Bacillus cereus LuxS Lsr-like Biofilm formation Related to foodborne illness 49 
Bacillus subtilis LuxS unknown Morphogenesis and social behavior a normal gut commensal in humans 50 
Borrelia burgdorferi LuxS unknown Increasing expression of the outer surface 
lipoprotein VlsE 
causative agent of Lyme disease 51 
Campylobacter jejuni LuxS unknown motility, biofilm formation and expression of 
flaA-B 
Causative agent of human gastroenteritis 52 
Clostridium difficile LuxS Unknown Toxin synthesis Causative agent of infectious diarrhea 53 
E. coli (EHEC) LuxS LsrB,a LsrR,b 
LsrKc 
Chemotaxis towards AI-2, swimming motility, 
colonization 
Causative agent of foodborne disease 54 
E. coli K12 LuxS LsrB,a LsrR,b 
LsrF,d LsrKc 
Motility, biofilm formation model organism strains 41, 55 
Enterococcus faecalis LuxS unknown Glyceraldehyde-3-phosphate dehydrogenase and 
malate dehydrogenase up-regulated by AI-2, 
biofilm formation 
endocarditis and bacteremia, urinary tract 
infections, meningitis and other infections in 
human 
56 
Haemophilus influenzae LuxS RbsBa Biofilm formation opportunistic pathogens that may 
cause  bacteremia, pneumonia, epiglottitis and 
acute bacterial meningitis 
57 





Klebsiella pneumoniae LuxS unknown Early steps of biofilm formation, 
lipopolysaccharide synthesis 
Causative agent of pneumonia, bloodstream 
infections, wound or surgical site infections, and 
meningitis 
59 
Listeria monocytogenes LuxS unknown Biofilm formation listeriosis 60 
Moraxella catarrhalis unknown unknown AI-2 promotes biofilm formation and antibiotic 
resistance 
Causative agent of infections of the respiratory 
system, middle ear, eye, central nervous system, 
and joints of humans 
61 
Mycobacterium avium Unknown unknown oxidative stress response up-regulated by AI-2 opportunistic pathogen that may cause fevers, 
diarrhea, malabsorption and anorexia 
62 
Neisseria meningitidis LuxS unknown meningococcal virulence Causative agent of meningitis 63 
Porphyromonas 
gingivalis 
LuxS  Modulates protease and haemagglutinin 
activities  
pathogen in early onset periodontitis 64 
Pseudomonas 
aeruginosa 
Unknown unknown Virulence factor production opportunistic pathogen that may cause infections 





LuxS LsrB,a LsrR,b 
LsrK,c LsrFd 
Pathogenicity island1gene expression 
And invasion into eukaryotic cells, biofilm 
formation, motility 
salmonellosis 39, 66 
Sinorhizobium meliloti Unknown SmlsrBa interferes with AI-2-regulated behaviors of other 
species 
nitrogen-fixing bacterium, forms 




LuxS unknown AI-2 may involve in spoilage of fish and shrimp a facultative anaerobe with the ability 
to reduce iron and manganese, associated with the 
odor of rotting fish 
68 
Staphyloccocus aureus LuxS unknown capsular polysaccharide synthesis a common cause of skin infections, respiratory 




LuxS unknown Controls genes involved in phenol-soluble 
modulin peptides, acetoin dehydrogenase, 
gluconokinase, bacterial apoptosis protein LrgB, 
Part of normal human flora but form biofilms on 









LuxS unknown antibiotic susceptibility part of the human bacteria flora, but can cause 




LuxS unknown antibiotic susceptibility and biofilm formation Associated with infective endocarditis and 
abscesses 
72 
Streptococcus gordonii LuxS unknown carbohydrate metabolism and biofilm formation  can cause acute bacterial endocarditis and form 
biofilm on clean tooth surfaces 
73 
Streptococcus mutans LuxS unknown Controls genes involved in biofilm formation, 
bacteriocin synthesis, competence, and acid 
tolerance 
Associated with tooth decay 74 
Streptococcus 
pneumoniae 
LuxS unknown Biofilm formation and lysis major cause of pneumonia, many types 
of pneumococcal infections and bacterial 
meningitis 
75 
Vibrio cholerae LuxS LuxPa Biofilm formation,protease and virulence 
production, and competence 
Cholera caused by infection of the intestine 26a, 76 
Vibrio harveyi  LuxS LuxPa Bioluminescence, biofilm formation, colony 
morphology, siderophore production, type III 
secretion and metalloprotease production 
a primary and opportunistic pathogen of marine 
animals 
20, 33, 77 
Vibrio fischeri 
(Aliivibrio fischeri) 
LuxS LuxPa Bioluminescence, biofilm formation Model strain 78 
Vibrio vulnificus LuxS LuxPa cytotoxicity A causative agent of septicaemia 79 
Yersinia pestis LuxS LsrBa regulates metabolic activities and oxidative stress 
genes 
a causative agent of the systemic invasive 
infectious disease/plague 
80 





Figure 1-7. Possible AI-2-based “druggable” targets. (1) LuxS; (2) AI-2 transporter 
(such as LsrB); (3) efflux pump for AI-2; (4) extracellular receptor for AI-2 (such as 
LuxP); (5) intracellular receptor for AI-2; (6) AI-2-regulated transcription factor or 
repressor (such as LsrR) (7) small regulatory RNA (sRNA) mediated QS circuit. 
 
The first AI-2 receptor that was structurally characterized was LuxP.30 LuxP is 
a membrane bound, extra cytosolic receptor that binds to the furanosyl borate diester 
form of AI-2, S-THMF borate 1-25d (Figure 1-8).23  
Following the crystal structure of LuxP/AI-2 complex, the Bassler and Hughson 
laboratories solved the structure of a second AI-2 receptor, LsrB (from S. typhimurium) 
in complex with a cyclic and hydrated form of AI-2, R-THMF 1-25f (Figure 1-9).39 
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Two other crystal structures of LsrB/AI-2 complexes (from Sinorhizobium meliloti67 
and Y. pestis80) have been structurally characterized. Also, in these complexes, AI-2 
was in the R-THMF 1-25f form, and the binding sites of the Sinorhizobium meliloti 
and Y. pestis LsrB are similar to that from S. typhimurium (Figure 1-10 and 1-11). 
 
Figure 1-8. A) Crystal structure of LuxP from V. harveyi in complex with AI-2 
(PDB code: 1JX6); B) AI-2 binding site of LuxP, showing protein residues that 





Figure 1-9. A) Crystal structure of LsrB from S. typhimurium, in complex with 
AI-2 (PDB code: 1TJY). B) AI-2 binding site of LsrB, showing protein residues 
that are within 3 Å of AI-2. 
 
Figure 1-10. A) Crystal structure of LsrB from Sinorhizobium meliloti (PDB 
code: 3EJW). B) AI-2 binding site of LsrB, showing protein residues that are 




Figure 1-11. A) Crystal structure of LsrB from Y. pestis (PDB code: 3T95). B) 
AI-2 binding site of LsrB, showing protein residues that are within 3 Å of AI-2. 
 
Figure 1-12. A) Crystal structure of LsrR from E. coli (PDB code: 4L4Z). B) AI-
2 binding site of LsrR, showing protein residues that are within 3 Å of AI-2. 
 
Recently, it has been reported that in E. coli, the key transcriptional regulator 
LsrR binds to AI-2 in its phospho 3-hydrated DPD form (1-30) as shown in Figure 1-
12.81 This discovery has facilitated the design of new generation of AI-2 analogs, which 
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will be discussed in the next chapter. 
 
Figure 1-13. A) Crystal structure of LsrF from E. coli (PDB code: 4P2V) B) AI-
2 binding site of LsrF, showing protein residues that are within 3 Å of AI-2. 
 
During the course of writing this thesis, the cyrstal structure of LsrF, a co-
enzynme A-dependent thiolase that catalyzes the terminal step of AI-2 metabolism, 
with the substrate phospho-HPD (1-25j) has been solved (Figure 1-13).41 This 
discovery has greatly expanded our understanding in AI-2 metabolism in bacterial cells. 
A simple way of discovering antagonists of a natural ligand is to modify that 
ligand. Several groups have therefore modified AI-2, with the hope of arriving at 
analogs that could interfere with AI-2 signaling. Janda and co-workers prepared and 
tested a panel of AI-2-like molecules (Figure 1-14). Using bioluminescence assay of 
V. harveyi, they found that the oxidation states at C2, C3 and C4, as well as the chirality 




Figure 1-14. Probing specificity of LuxP binding site with AI-2-like molecules.82 
 
Figure 1-15. C1-modified AI-2 molecules synthesized by Janda and Sintim.83,84 
Janda and Sintim have also synthesized a panel of C1 AI-2 analogs (Figure 1-
15) and tested for activities in V. harveyi,83 E. coli and Salmonella.84 In V. harveyi, C1-
substituted AI-2 analogs act as synergistic agonists, in that they do not have any 
agonism on their own but enhance the agonism of AI-2. 
AI-2 is a highly functionalized molecule and difficult to purify on column 
chromatography. In the presence of adventitious acid, AI-2 also decomposes. Doutheau 
and co-workers first demonstrated that acetate protected analogs of AI-2 were as 
effective as natural AI-2 in inducing bioluminescence in V. harveyi and β-galactosidase 
in S. typhimurium, but had the added advantage of being stable (Figure 1-16).85 Later, 
Sintim extended this idea to make acetate protected C1 analogs of AI-2 and also 
showed that these could be deprotected in vivo by bacteria esterases and act as AI-2 




Figure 1-16. Acetate- and ester-protected AI-2 and analogs developed by Sintim and 
Doutheau.85,86  
Recently, Ventura and co-workers showed that C5-modified AI-2 analogs were 
synergistic agonists in E. coli and strong agonists in V. harveyi (Figure 1-17).87 
 
Figure 1-17. C5 analogs of AI-2 developed by Ventura and co-workers (1-53 to 1-60), 
which analogs contain stereochemical diversity at the C4 and C5 positions.87 
 
Other AI-2 inhibitors, targeting AI-2 synthase and receptors, that are not based 
on the AI-2 scaffold have also been reported. For excellent reviews, see those by 




1.4 AI-1 mediated quorum sensing 
In the past decades, there have been extensive studies done on intraspecies 
quorum sensing molecules, AI-1, most commonly found in Gram-negative bacteria. 
Since chemists and microbiologists may call these molecules by different names, to 
clear the confusion, it is necessary to clarify the nomenclature (Figure 1-18). AI-1 
usually refers to lactone-based QS autoinducers, one of the major classes of QS 
signaling molecules. AHL is a chemical structure featuring a N-acylhomoserine lactone 
scaffold whereas HSL is just the homoserine lactone moiety. Often times the side chain 
of AI-1 molecules has a 3-oxoacyl function group, so they are named 3-oxo-HSL for 
short. 
 
Figure 1-18. Nomenclature of AI-1. 
Table 1-3 listed some representative natural AI-1 molecules and the 
corresponding bacteria that produce them, as well as QS phenotypes. Each bacterial 
species senses specific AI-1, which minly differ by the length and functionality on the 
acyl chain. The first AI-1 mediated quorum sensing system was discovered in V. 
fischeri, which uses 3-oxo-C6-HSL as the autoinducer.19a, 21 LuxI is the synthase while 
LuxR is the receptor of 3-oxo-C6-HSL. The majority of later discovered quorum 
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sensing systems are LuxI/R type. AI-1 circuit in V. fisheri is shown below in Figure 1-
19. 
 
Figure 1-19. AI-1 signaling in V. fischeri. 
In the past decades, the community has been heavily focused on chemical 
modifications on either the lactone head group or the acyl chain, or both of AI-1. Table 
1-4 highlights some biologically active AHL analogs that have been made.  
In early years, studies were focused on changing the length of acyl chain and 
generally the chain lengths were important to the activities as even a small change in 
carbon number from the native AHLs could result in totally different outcome.90 All 
the native AHLs are L-conformers because of their biosynthesis process.91 Synthetic 
D-AHLs have been investigated but were found to be significantly less active than the 
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L-AHLs, except very few examples.92 Later on, more modifications on lactone head 
group were explored however in many cases, these changes lead to less active 
compounds. Out of the lactone mimics, thiolactones were relatively popular not only 
because they somehow retain the electronic properties of the parent lactone ring but 
also they are more stable towards hydrolysis by lactonases. Some potent antagonists 
were found based on this head group.93 On the chain side, the incorporation of aromatic 
rings often yields good antagonists and agonists.93-94 
The goal of this thesis was to utilize synthetic chemistry tools to make analogs 
of AI-2 and AI-1 based on DPD and homoserine lactone structures, respectively. These 
medicinal chemistry modifications would be screened for their agonist or antagosnist 
activities in quorum sensing of different bacteria. In turn, the results from the screening 
would further guide us to design the next generation of AI-like molecules. The studies 
in this thesis would be a valuable addition to the ultimate goal that one day, quorum 
sensing inhibition strategy could be a new therapy against bacterial infectious diseases.
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Organism AI-1 LuxI/R homologs QS phenotypes 
A. tumefaciens 
3-oxo-C8-HSL 1-61 
TraI/R Plasmid conjugation 
B. cenocepacia 
C8-HSL 1-62 
CepI/R, CciI/R Biofilm, swarming, motility, virulence 
C. violaceum 
C6-HSL 1-63 
CviI/R Exoenzymes, cyanide, pigment 
E. carotovora 
3-oxo-C6-HSL 1-64 













LuxM/N Bioluminescence, biofilm, TTS, protease 
Table 1-3. Representative AHL structures and their corresponding organism, synthases/receptors and QS phenotypes. 
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Table 1-4. Significant AHL analogs and their activities. 
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Chapter 2. AI-2 analogs selectively modulate QS in bacteria 
(The this section was modified from my publication86) 
The Sintim group has shown over the years that modification of AI-2 at the C1 position 
gives analogs that can antagonize the action of AI-2 in a variety of bacteria.83a, 84c, d, 86 
Chemists in the Sintim group have therefore been engaged in the development of 
methodologies to make modified analogs of AI-2, with the ultimate goal of modulating 
bacterial quorum sensing using these synthetic molecules.  
2.1 Improvement in AI-2 synthesis. 
A former member of the Sintim group, Dr Jacqueline Smith, developed a facile, 
two-flask synthesis of AI-2, which is amenable to the generation of a variety of C1 AI-
2 analogs (Scheme 2-1).83a The key step in this synthesis is the Aldol condensation 
between various diazocarbonyls 2-3 and a commercially available 2-(tert-
butyldimethylsiloxy)acetaldehyde (2-4). The diazocarbonyls 2-3, which are used in 
Sintim’s synthesis, could be obtained from the requisite acyl chloride 2-1 and 
diazomethane (2-2). The resulting diazocarbonyls 2-3 were then condensed with 2-
(tert-butyldimethylsiloxy)acetaldehyde (2-4) to afford diazo diol intermediates 2-6, 
after deprotection of the silyl group with tetra-butyl ammonium fluoride. Column 
chromatography purification of the diazo diol followed by oxidation with dimethyl 




Scheme 2-1. Synthesis of DPD and analogs developed by Sintim and co-workers. 
When I first joined the Sintim group, my first task was to re-synthesize a library 
of C1-substituted AI-2 analogs (with linear, branched, cyclic, and, aromatic C1 groups, 
Figure 2-1), which were first synthesized by Dr. Smith.84c, d The goals of re-
synthesizing Dr. Smith’s compounds were to learn how to make AI-2 analogs, using 
the diazo carbonyl methodology and to provide more compounds for evaluation of 
biological activities. During the synthesis, I found that the first step, involving acyl 
chloride 2-1 and large excess (4-6 equiv) of diazomethane (2-2) was not efficient. This 
was because the HCl generated would degrade the desired diazocarbonyls 2-3 to an α-
chloroketone and thus much more diazomethane (2-2) was needed to scavenge HCl 
(Scheme 2-2). Thus this step was low yielding with several byproducts, which 
purification difficult. Moreover, diazomethane (2-2) is toxic, volatile and shock 
sensitive, and therefore not ideal to prepare on large scale. In order to scavenge the 
generated HCl base was needed (note that Smith’s procedure only used 0.2 equiv. DBU) 
and the choice of the base was critical because the base could also deprotonate the 
acidic α-hydrogen on the acyl chloride 2-1 and result in a ketene product 2-33 (Scheme 
2-2). I discovered that adding 1.1 equiv of CaO to scavenge the generated HCl allowed 
for a reduction of the diazomethane that was used (from 4-6 equiv. in Smith’s protocol 
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to 1,5 equiv. in my protocol), and also the yield of the reaction was improved to over 
90%, with little byproduct.106 
Figure 2-1. First generation of C1 substituted AI-2 analogs synthesized and evaluated 
for biological activities.83a, 84c, d 




2.2 A pro-drug approach for selective modulation of AI-2 mediated bacterial cell-
to-cell communication. 
(Section 2.2 was published as Min Guo, Sonja Gamby, Shizuka Nakayama, 
Jacqueline Smith and Herman Sintim. Sensors, 2012, 12, 3762-72)86 
2.2.1 Introduction 
Several groups have been interested in the development of analogs of the 
universal quorum sensing molecule, AI-2.83b, 84a, 107 Analogs of AI-2 have been shown 
to either act as synergistic agonists in some Vibrio species83 or antagonist84d in enteric 
bacteria, such as E. coli and S. typhimurium. Interestingly, it has been demonstrated 
that the nature of the C1 acyl group in AI-2 analogs confers specificity in disrupting 
QS processes in a variety of bacteria.84d For example, hexyl-DPD (2-13) inhibits AI-2-
mediated lsr expression in E. coli whereas this same molecule is ineffective against AI-
2-mediated lsr expression in the analogous enteric bacteria, S. typhimurium. On the 
other hand, isobutyl DPD (2-16) could inhibit AI-2-mediated lsr expression in S. 
typhimurium, implying that subtle differences in the C1 substituents of AI-2 could 
result in significant differences in biological response.84d 
One of the limitations of the use of AI-2 analogs in selectively modulating 
bacterial behavior is the instability of these analogs. At high concentrations, it has been 
shown that AI-2 form dimers (2-34, see Figure 2-2), which are not biologically 
active.108 This makes the purification of AI-2 or analogs on silica gel problematic and 
most studies that use synthetic AI-2 use unpurified material. Others have attempted to 
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solve the instability issue associated with AI-2 by making ester derivatives that 
hydrolyze in vivo to release active autoinducers.85 This strategy is promising in 
delivering purer and more stable AI-2 analogs that could be used in studying bacterial 
communication, with implications for disease control or synthetic biology applications. 
However, detailed study that correlates the nature of the ester group on AI-2 and 
biological activity has not been described. Additionally, as analogs of AI-2 are 
emerging as potent anti-QS molecules,84d it is of interest to investigate if these QS 
signaling inhibitors could also be protected as ester “pro-drugs” and still retain their 
inhibitory activity. If different bacteria processed ester-protected AI-2 analogs 
differently, then one could selectively modulate the activity of specific bacteria in an 
ecosystem via the use of differently protected AI-2 analog. 
 
Figure 2-2. Structure of AI-2 dimer. 
2.2.2 Results and discussion 
The syntheses of bis-ester protected AI-2 and analogs 19–30 were achieved via 
the strategy shown in Scheme 2-3.83a, 84d Briefly, an aldol reaction between 
diazocarbonyls 2-35 to 2-37 and 2-(tert-butyldimethylsilyloxy) acetaldehyde 2-4 
afforded diazodiols 2-38 to 2-40, after deprotection of the TBS group with TBAF. 
Oxidation of the diazo group in diazodiols 2-38 to 2-40 afforded AI-2 or analogs but 
38 
 
for the production of ester protected AI-2 and analogs, it was important to perform the 
esterification step first to give bis-ester 2-45 to 2-56 before the oxidation of the diazo 
bis-ester to give targeted compounds 2-57 to 2-68. 
Scheme 2-3. Synthetic strategy for making bis-ester protected AI-2 analogs. Reagents 
and conditions: (a) diazomethane, 0 °C, (b) tert-butyl-siloxyacetaldehyde, DBU (1,8 
diazabicycloundec-7-ene), CH3CN, RT (c) TBAF/THF. DCM= dichloromethane; 
DMDO = dimethyldioxirane. 
With the various AI-2 or analog ester derivatives (methyl to pentyl esters, 
Figure 2-3) in hand, we proceeded to investigate the biological profiles of these esters. 
We have previously demonstrated that AI-2 analogs with longer C1-acyl chains 
permeate more readily into bacterial cells than shorter chains.109  This is presumably 
due to the favorable interactions of the alkyl chain with the phospholipid of the bacterial 
membrane. Based on this earlier work, we hypothesized that the longer chain ester 
derivatives (such as butyl or pentyl) would permeate more readily into bacterial cells 
than the shorter chain analogs, such as the methyl ester series.109 However, if the 
cellular esterases were sensitive to the size of the esters, then the longer chain analogs 
would be hydrolyzed slower than the shorter chain ones. Because biological activity of 
ester prodrugs is dependent on permeation and prodrug activation and both of these 
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processes would depend on the organism in question, it is not always easy to predict a 
priori which ester group is most suitable for derivatizing biologically active molecules. 
Figure 2-3. Compounds evaluated as bis-ester protected AI-2 analogs. 
Bis-ester-protected AI-2 analogs (with different ester chains; methyl, propyl, 
butyl and pentyl) were all effective lsr expression inducers in E. coli (see Figure 2-4). 
For S. typhimurium, it appears that LsrR is not as good a repressor (compared to E. 
coli) and significant expression of the lacZ gene was observed even in the absence of 
added DPD (see control, Figure 2-4). Nonetheless, it is apparent that more LacZ 
protein was present in S. typhimurium in the presence of AI-2 than when AI-2 was not 
present [about 30% more LacZ present when AI-2 is added; see Figure 2-4, compare 




Figure 2-4. Black bars: AI-2 or analogs-mediated expression of β-galactosidase in S. 
typhimurium (MET715: LuxS−). Red bars: AI-2 or analogs-mediated expression of β-
galactosidase in E. coli LW7/LuxS−. AI-2 or bis-ester analogs of AI-2 (20 µM) were 
added to the bacterial strains, which do not produce their own AI-2. Compounds 2-57 
to 2-60 represent ester-protected DPD analogs: 2-57: DPD bis-methyl ester; 2-58: DPD 
bis-propyl ester; 2-59: DPD bis-butyl ester; 2-60: DPD bis-pentyl ester. (Done by Dr. 
Shizuka Nakayama, a former postdoc in the Sintim group). 
Therefore, even if lacZ expression is not solely controlled by AI-2, one can 
safely conclude that AI-2 plays some role in lacZ expression in the S. typhimurium.40 
The origin of “leaky” lacZ expression in the absence of LuxS, which makes AI-2, could 
be due to myriads of factors, such as a lower affinity of LsrR to the LsrR DNA binding 
region in S. typhimurium (compared to E. coli) or a higher concentration of other 
phosphorylated AI-2-like molecules (such as ribulose-5-phosphate) in S. typhimurium 
(compared to E. coli) or lower levels of LsrR in S. typhimurium (compared to E. coli) 
or even non-enzymatic production of AI-2 from ribulose-5-phosphate.110 Without 
experimental data to pinpoint the origin of the differential lsr expression in S. 
typhimurium (compared to E. coli), it is dangerous to make definitive statements about 
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the origin of this difference. Despite this high LacZ background in S. typhimurium, we 
can still conclude that the majority of the ester protected DPD analogs were not as good 
as DPD in inducing lsr expression in S. typhimurium, and only bis-butyl DPD appears 
to be as good as DPD (see Figure 2-4). It is important to note that DPD/AI-2 gets into 
S. typhimurium via a ribose transporter, such as LsrB, whereas the analogs would have 
to diffuse into the cells, probably via passive diffusion through the membrane. Hence 
the marginal differences in activity observed between bis-butyl DPD and the other 
ester-protected DPD could be due to differences in membrane transport. Next, we 
investigated the antagonistic profile of the bis-ester analogs of isobutyl DPD in both E. 
coli and S. typhimurium. Isobutyl DPD 2-16 is an antagonist of AI-2-mediated QS in 
both E. coli and S. typhimurium and stable versions of this analog have the potential to 
disrupt QS processes in these enteric bacteria, which sometimes cause food-borne 
diseases. For this assay, AI-2 was added to a LuxS-deficient strain of E. coli (LW7) or 
S. typhimurium (MET715) to induce lsr expression via the derepression of LrsR by 
phospho-AI-2.111 In E. coli, bis-methyl and bis-propyl DPD analogs were as effective 




Figure 2-5. Inhibition of AI-2-mediated β-galactosidase expression in S. typhimurium 
(Black Bars) and E. coli (Red Bars) with various bis-ester analogs of isobutyl DPD. 
[AI-2] = 20 µM, [analogs] = 20 µM. Compounds 23-26 represent ester protected 
isobutyl DPD analogs; 23: isobutyl DPD bis-methyl ester, 24: isobutyl DPD bis-propyl 
ester, 25: isobutyl DPD bis-butyl ester, 26: isobutyl DPD bis-pentyl ester. (Done by Dr. 
Shizuka Nakayama, a former postdoc in the Sintim group). 
Increasing the length of the ester chain to butyl or pentyl either reduced (butyl) 
or abrogated (pentyl) the inhibitory profile of the DPD analog. In E. coli, the same trend 
was also observed for the bis-ester derivatives of hexyl DPD (bis-methyl and bis-propyl 
analogs, but not butyl or pentyl derivatives, were QS inhibitors, Figure 2-6).   
In S. typhimurium, however, none of the bis-ester protected isobutyl DPD 
analogs were able to antagonize the action of AI-2. Addition of isobutyl DPD to S.  
typhimurium however decreased lacZ expression by about 50% (compare black bar 
corresponding to “isobutyl DPD” to black bar corresponding to “LuxS- + DPD”  in 
Figure 2-5). Thus, S. typhimurium and E. coli have similar QS systems, but differences 
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in the processing of ester analogs of isobutyl DPD allows for the selective modulation 
of QS processing in E. coli, but not in S. typhimurium. 
 
Figure 2-6. Inhibition of AI-2-mediated β-galactosidase expression in E. coli with 
various bis-ester analogs of hexyl DPD. [DPD] = 20 µM, [analogs] = 20 µM. 
Compounds 2-65 to 2-68 represent ester protected hexyl DPD analogs; 2-65: hexyl 
DPD bis-methyl ester; 2-66: hexyl DPD bis-propyl ester; 2-67: hexyl DPD bis-butyl 
ester; 2-68: hexyl DPD bis-pentyl ester. (Done by Dr. Shizuka Nakayama, a former 
postdoc in the Sintim group).  
 
2.2.3 Conclusion 
In conclusion, we have shown that ester derivatives of DPD analogs can be 
hydrolyzed inside bacterial cells to reveal the biologically active diol unit for quorum 
sensing disruption. We note that it is possible to achieve selectivity of QS modulation 
amongst closely related bacteria (in our case, between E. coli and S. typhimurium) via 
the use of ester protection of the diol unit of AI-2. The origin of this selectivity remains 
unknown at this moment, but it could be a number of several factors, including selective 
permeation of the analogs or different sensitivities of the esterases required for analog 
hydrolysis in the different bacteria (Figure 2-7). Future work will be aimed at obtaining 
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a more in depth molecular understanding of these interesting observations. This work 
adds to the growing list of different strategies that can be used to intercept AI-2 
signaling in diverse bacteria.112 
 
Figure 2-7. Proposed model of action in enteric bacteria. Ester protected DPD analogs 
diffuse into the cell, where esterases hydrolyze the ester pro-DPD and analogs and the 
DPD or analogs are subsequently phosphorylated by LsrK. 
 
2.2.4 Experimental Section 
Chemical Synthesis 
a) Generation of Diazomethane 
Diazomethane is toxic, valitile and shock sensitive. The synthesis was 
recommended to be at small scale with shield and reagent Diazald® (Sigma-Aldrich) as 
well as a diazomethane generator apparatus (Sigma-Aldrich), following the protocol 
provided by Sigma-Aldrich. Briefly, a solution of Diazald® (5 g) in diethyl ether (45 
mL) was slowly added to a solution of KOH (5 g) in mixed solvent (water (8 mL) and 
ethanol (10 mL)) at 65 °C over 20 min. The generated diazomethane and the diethyl 
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ether solvent distilled and was trapped in a collecting vessel using a dry ice/isopropanol 
bath to give diazomethane as a solution in diethyl ether (ca. 0.4-0.5 M). 
b) Addition of Diazomethane to Acyl Chlorides 
To a solution of diazomethane (3 equiv.) in diethyl ether was added an acyl 
chloride (1 equiv.) dropwise at 0 °C. The resulting solution was allowed to stir for 
another 2 h and warmed up gradually to room temperature. The solvent was removed 
under vacuum and the diazocarbonyl residue (yellow liquid) was used for the next step 
without further purification. 
c) Synthesis of Diazodiols 
DBU (0.16−0.20 equiv.) and 2-(tert-butyldimethylsilyloxy) acetaldehyde 
(1−1.5 equiv.) were added to a solution of the diazocarbonyl (crude, 1 equiv.) in 
anhydrous acetonitrile (0.2 M). The reaction was stirred at room temperature under 
nitrogen for 4−8 h and monitored by TLC. Upon disappearance of starting material, the 
reaction was quenched with sodium bicarbonate. The organic layer was extracted with 
dichloromethane (3 × 20 mL) and dried with magnesium sulfate. 
The solvent was evaporated under reduced pressure. To a solution of crude product in 
anhydrous tetrahydrofuran at 0 °C, TBAF was added (1−2 equiv.). The solution was 
allowed to warm to room temperature and stirred for 1−3 h under nitrogen. The solvent 
was evaporated, and the crude product was purified by column chromatography. The 
products eluted as yellow oils using 1:3 to 3:2 ethyl acetate/hexane as the mobile phase. 
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d) Synthesis of Ester Protected Diazo Compounds 
To a stirring solution of diazodiol (1 equiv.) catalytic 4-dimethyl aminopyridine 
(DMAP) and suspended 4Å molecular sieves in dichloromethane (DCM) was added 
the requisite anhydride. The reaction was allowed to gently stir at room temperature for 
2-4 h until complete disappearance of starting material was indicated by TLC. The 
crude reaction mixture was filtered washed with saturated NaHCO3 aqueous solution 
and the organic phase was extracted with more DCM. The combined organic phases 
were dried with anhydrous MgSO4 and the solvent was evaporated at reduced pressure. 
The crude product was purified by column chromatography. The products eluted as 
yellow oils using 1:3 to 1:2 ethyl acetate/hexane as the mobile phase (Rf = 0.2). 
e) Synthesis of DPDs  
Dimethyldioxirane in acetone (15−20 mL) was added dropwise to a solution of 
ester protected diazodiol (1 equiv.) in acetone (1−2 mL). The reaction was allowed to 
stir at room temperature (1−2 h) until complete disappearance of starting material was 
indicated by TLC (loss of UV activity). Solvent and excess reagents were evaporated 
under reduced pressure.  
Bacterial Strains and Growth Conditions  
Table 2-1 lists the bacterial strains used in this study. S. typhimurium and E. 
coli strains were cultured in Luria−Bertani medium (LB, Sigma). These antibiotics 
were used for the following strains: (60 μg mL−1) kanamycin for S. typhimurium 
(MET715) and (50 μg mL−1) ampicillin for E. coli (LW7) 
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Strain Relevant genotype and/or property 
 Escherichia coli 
LW7 W3110ΔlacU160-tna2 ΔluxS :: Kan 
(LuxS-deficient: does not produce AI-2) 
 Salmonella typhimurium 
MET715 rpsl putRA :: Kan-lsr-lacZYA luxS :: T-POP 
(LuxS-deficient: does not produce AI-2) 
Table 2-1. Bacterial strains used in this study. 
Measurement of the QS Response (lsr Expression)  
The QS response indicated by lsr gene expression was analyzed in pure culture 
studies by culturing E. coli LW7 pLW11 and S. typhimurium MET715 overnight at 30 
oC in LB medium supplemented with appropriate antibiotics as stated previously. These 
cells were then diluted into fresh LB medium (with antibiotics) and grown to an OD600 
of 0.4−0.8 at 37 °C, 250 rpm. Cells were then collected by centrifugation at 10,000 × 
g for 10 min and resuspended in 10 mM phosphate buffer. AI-2 (20 μM) and the 
respective analog (20 μM) were added to the E. coli or S. typhimurium suspension for 
2 h at 37 °C. AI-2 dependent β-galactosidase production was quantified by the Miller 




Scheme 2-4. Synthesis of ester protected diazodiol. 
2-45 
3-diazo-4-oxopentane-1,2-diyl diacetate (2-45): To a solution of methyl 
diazodiol 2-3883a (89 mg, 0.62 mmol), DAMP (15 mg, 0.2 equiv.) and suspended 
4A molecular sieves (0.2 g) in anhydrous dichloromethane (DCM) was added 
acetic anhydride (0.12 mL, 2.0 equiv.). The reaction was gently stirred at room 
temperature overnight. The reaction was quenched with saturated aqueous 
NaHCO3 solution. The organic and aqueous layers were separated and the organic 
layer was washed with brine and dried over anhydrous MgSO4. The solvent was 
removed in vacuo and the residue was purified on silica gel, using 3:4 ethyl 
acetate/hexane as the mobile phase (Rf = 0.2). The product eluted as a yellow oil 
(yield = 90 mg, 64%). 
2-46 
3-diazo-4-oxopentane-1,2-diyl dibutyrate (2-46): To a solution of methyl diazodiol 
2-38 (23 mg, 0.16 mmol), DMAP (4 mg, 0.2 equiv.) and suspended 4A molecular 
sieves (0.1 g) in anhydrous dichloromethane (DCM) was added butyric anhydride (0.05 
mL, 2 equiv.). The reaction was stirred at room temperature overnight. The reaction 
was quenched with saturated aqueous NaHCO3 solution. The organic and aqueous 
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layers were separated and the organic layer was washed with brine and dried over 
anhydrous MgSO4. The solvent was removed in vacuo and the residue was purified on 
silica gel, using 1:5 ethyl acetate/hexane as the mobile phase (Rf = 0.2). The product 
eluted as a yellow oil (yield = 23 mg, 51%). 
2-47 
3-diazo-4-oxopentane-1,2-diyl dipentanoate (2-47): To a solution of methyl 
diazodiol 2-38 (23 mg, 0.16 mmol), DMAP (4 mg, 0.2 equiv.) and suspended 4A 
molecular sieves (0.1 g) in anhydrous dichloromethane (DCM) was added butyric 
anhydride (0.05 mL, 2 equiv.). The reaction was stirred at room temperature overnight. 
The reaction was quenched with saturated aqueous NaHCO3 solution. The organic and 
aqueous layers were separated and the organic layer was washed with brine and dried 
over anhydrous MgSO4. The solvent was removed in vacuo and the residue was 
purified on silica gel, using 1:5 ethyl acetate/hexane as the mobile phase. The product 
eluted as a yellow oil (yield = 27 mg, 54%). 
2-48 
3-diazo-4-oxopentane-1,2-diyl dihexanoate (2-48): To a solution of methyl diazodiol 
2-38 (23 mg, 0.16 mmol), DMAP (4 mg, 0.2 equiv.) and suspended 4A molecular 
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sieves (0.1 g) in anhydrous dichloromethane (DCM) was added butyric anhydride (0.05 
mL, 2 equiv.). The reaction was stirred at room temperature overnight. The reaction 
was quenched with saturated aqueous NaHCO3 solution. The organic and aqueous 
layers were separated and the organic layer was washed with brine and dried over 
anhydrous MgSO4. The solvent was removed in vacuo and the residue was purified on 
silica gel, using 1:5 ethyl acetate/hexane as the mobile phase. The product eluted as a 
yellow oil (yield = 38 mg, 67%). 
 
Scheme 2-5. Oxidation of diazo moiety into carbonyl. 
2-57 
3,4-dioxopentane-1,2-diyl diacetate (2-57): To a solution of methyl diazo diacetate 
2-45 (20 mg, 0.088 mmol) in acetone (1 mL) was added dimethyldioxirane acetone 
solution (2.5 mL, ca. 0.07–0.09 M). The resulting mixture was stirred for 1 h and 
solvent and excess reagents were removed under reduced pressure to obtain 2-57 as 




3,4-dioxopentane-1,2-diyl dibutyrate (2-58): To a solution of methyl diazo dibutyrate 
2-46 (23 mg, 0.081 mmol) in acetone (1 mL) was added dimethyldioxirane acetone 
solution (2.5 mL, ca. 0.07-0.09 M). The resulting mixture was stirred for 1 h and 
solvent and excess reagents were removed under reduced pressure to obtain 2-58 as 
bright yellow oil (yield = 22 mg, quantitative). 
2-59 
3,4-dioxopentane-1,2-diyl dipentanoate (2-59): To a solution of methyl diazo 
dipentanoate 2-47 (27 mg, 0.086 mmol) in acetone (1 mL) was added dimethyldioxirane 
acetone solution (2.5 mL, ca. 0.07–0.09 M). The resulting mixture was stirred for 1 h 
and solvent and excess reagents were removed under reduced pressure to obtain 2-59 
as bright yellow oil (yield = 26 mg, quantitative). 
2-60 
3,4-dioxopentane-1,2-diyl dihexanoate (2-60): To a solution of methyl diazo 
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dihexanoate 2-48 (38 mg, 0.112 mmol) in acetone (1 mL) was added dimethyldioxirane 
acetone solution (2.5 mL, ca. 0.07–0.09 M). The resulting mixture was stirred for 1 h 
and solvent and excess reagents were removed under reduced pressure to obtain 2-60 
as bright yellow oil (yield = 36.8 mg, quantitative). 
 
Scheme 2-6. Note: Both the diazoketones and diketones did not have good MS 
spectrum (presumably due to decomposition under the MS conditions. Therefore, 
further MS characterization was done by adding phenyl diamine to the diketones and 
stirred overnight to convert the diketones into quinoxalines, see Scheme above (this is 
a standard practice). MS data is therefore reported for the quinoxaline derivatives. 
NMR and MS data: NMR spectra were measured on Bruker AV-400, Bruker DRX-
400 (1H at 400 MHz, 13C at 100 MHz). Data for 1H-NMR spectra are reported as 
follows: chemical shift (ppm, relative to residual solvent peaks or indicated external 
standards; s = singlet, t = triplets, m = multiplet), coupling constant (Hz), and 
integration. Data for 13C-NMR are reported in terms of chemical shift (ppm) relative to 
residual solvent peak. Mass spectra (MS) were recorded by JEOL AccuTOF-CS (ESI 
positive, needle voltage 1800~2400 eV). 
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(Note, MS of diazo compounds could not be obtained due to decomposition of the diazo 
moiety under MS conditions). 
2-45 
3-diazo-4-oxopentane-1,2-diyl diacetate (2-45): 1H NMR (CDCl3, 400 MHz) δ: 
5.85–5.73 (m, 1H), 4.45–4.34 (m, 1H), 4.31–4.17 (m, 1H), 2.19 (s, 3H), 2.03 (s, 3H), 
2.01 (s, 3H). 13C NMR (CDCl3, 100 MHz) δ: 188.6, 170.1, 169.6, 68.5, 65.7, 63.5, 25.4, 
20.7, 20.5. (carbon signal next to diazo group might not show up) 
2-46 
3-diazo-4-oxopentane-1,2-diyl dibutyrate (2-46): 1H NMR (CDCl3, 400 MHz) δ: 
5.93–5.83 (m, 1H), 4.55–4.43 (m, 1H), 4.38–4.27 (m, 1H), 2.38–2.28 (m, 4H), 2.26 (s, 
3H), 1.73–1.59 (m, 4H), 1.01–0.89 (m, 6H). 13C NMR (CDCl3, 100 MHz) δ: 173.3, 
172.7, 65.9, 63.7, 37.0, 36.3, 36.2, 31.3, 25.9, 18.7, 14.0, 13.9. (carbon signal next to 
diazo group might not show up) 
2-47 
3-diazo-4-oxopentane-1,2-diyl dipentanoate (2-47): 1H NMR (CDCl3, 400 MHz) δ: 
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5.93–5.82 (m, 1H), 4.54–4.43 (m, 1H), 4.37–4.26 (m, 1H), 2.41–2.29 (m, 4H), 2.26 (s, 
3H), 1.67–1.54 (m, 4H), 1.42–1.28 (m, 4H), 0.97–0.85 (m, 6H). 13C NMR (CDCl3, 100 
MHz) δ: 189.0, 173.4, 172.9, 67.0, 66.0, 63.7, 34.1, 34.0, 27.2, 25.9, 22.6, 22.5, 14.0. 
2-48 
3-diazo-4-oxopentane-1,2-diyl dihexanoate (2-48): 1H NMR (CDCl3, 400 MHz) δ: 
5.92–5.82 (m, 1H), 4.55–4.42 (m, 1H), 4.37–4.26 (m, 1H), 2.40–2.28 (m, 4H), 2.26 (s, 
3H), 1.68–1.56 (m, 4H), 1.38–1.25 (m, 8H), 0.96–0.83 (m, 6H). 13C NMR (CDCl3, 100 
MHz) δ: 173.4, 172.9, 66.0, 63.7, 34.4, 34.3, 31.6, 25.9, 24.9, 22.7, 14.3. (carbon signal 
next to diazo group might not show up) 
2-49 
3-diazo-6-methyl-4-oxoheptane-1,2-diyl diacetate (2-49): 1H NMR (CDCl3, 400 
MHz) δ: 5.85–5.76 (m, 1H), 4.44–4.34 (m, 1H), 4.32–4.21 (m, 1H), 2.28 (d, J = 6.7 
Hz, 2H), 2.15–2.07 (m, 1H), 2.03 (s, 3H), 2.01 (s, 3H), 0.89 (d, J = 8.0 Hz, 6H). 13C 
NMR (CDCl3, 100 MHz) δ: 170.5, 169.9, 66.3, 63.8, 47.1, 26.0, 22.8, 22.7, 21.0, 20.8. 




3-diazo-6-methyl-4-oxoheptane-1,2-diyl dibutyrate (2-50): 1H NMR (CDCl3, 400 
MHz) δ: 5.92–5.81 (m, 1H), 4.50–4.39 (m, 1H), 4.34–4.22 (m, 1H), 2.37–2.21 (m, 6H), 
2.18–2.04 (m, 1H), 1.69-1.54 (m, 4H), 0.96-0.85 (m, 12H). 13C NMR (CDCl3, 100 
MHz) δ: 173.2, 172.6, 66.1, 63.6, 47.2, 36.2, 36.1, 26.0, 22.8, 22.7, 18.7, 18.6, 13.9. 
(carbon signal next to diazo group might not show up) 
2-51 
3-diazo-6-methyl-4-oxoheptane-1,2-diyl dipentanoate (2-51): 1H NMR (CDCl3, 400 
MHz) δ: 5.94–5.82 (m, 1H), 4.53–4.44 (m, 1H), 4.40–4.29 (m, 1H), 2.41–2.29 (m, 6H), 
2.23–2.10 (m, 1H), 1.67–1.56 (m, 4H), 1.41-1.31 (m, 4H), 0.98–0.89 (m, 12H). 13C 
NMR (CDCl3, 100 MHz) δ: 180.0, 173.5, 172.9, 66.2, 63.7, 47.3, 34.2, 34.1, 34.0, 27.3, 
22.6, 22.5, 14.1, 14.0. (carbon signal next to diazo group might not show up) 
2-52 
3-diazo-6-methyl-4-oxoheptane-1,2-diyl dihexanoate (2-52): 1H NMR (CDCl3, 400 
MHz) δ: 5.96–5.82 (m, 1H), 4.54–4.42 (m, 1H), 4.40–4.26 (m, 1H), 2.42–2.26 (m, 6H), 
2.22–2.09 (m, 1H), 1.68–1.56 (m, 4H), 1.38–1.22 (m, 8H), 1.00–0.93 (m, 6H), 0.93–
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0.85 (m, 6H). 13C NMR (CDCl3, 100 MHz) δ: 173.4, 172.8, 66.2, 63.7, 47.3, 34.3, 31.6, 
24.9, 22.7, 14.3. (carbon signal next to diazo group might not show up) 
2-53 
3-diazo-4-oxodecane-1,2-diyl diacetate (2-53): 1H NMR (CDCl3, 400 MHz) δ: 5.95–
5.85 (m, 1H), 4.54–4.43 (m, 1H), 4.41–4.29 (m, 1H), 2.49 (t, J = 7.3 Hz, 2H), 2.12 (s, 
3H), 2.11 (s, 3H), 1.69–1.60 (m, 2H), 1.38–1.27 (m, 6H), 0.91 (t, J = 6.9 Hz, 3H). 13C 
NMR (CDCl3, 100 MHz) δ: 170.7, 170.1, 66.4, 64.0, 38.6, 31.9, 29.2, 24.8, 22.9, 21.2, 
21.0, 14.4. (carbon signal next to diazo group might not show up) 
2-54 
3-diazo-4-oxodecane-1,2-diyl dibutyrate (2-54): 1H NMR (CDCl3, 400 MHz) δ: 
5.96–5.85 (m, 1H), 4.56–4.46 (m, 1H), 4.40–4.28(m, 1H), 2.53–2.43 (m, 2H), 2.38–
2.29 (m, 4H), 1.72–1.61 (m, 6H), 1.37–1.25 (m, 6H), 1.02–0.94 (m, 6H), 0.94–0.87 (m, 
3H). 13C NMR (CDCl3, 100 MHz) δ: 173.3, 172.7, 66.2, 63.7, 36.3, 36.2, 31.9, 29.2, 




3-diazo-4-oxodecane-1,2-diyl dipentanoate (2-55): 1H NMR (CDCl3, 400 MHz) δ: 
5.95–5.84 (m, 1H), 4.56–4.43 (m, 1H), 4.40–4.27 (m, 1H), 2.55–2.44 (m, 2H), 2.40–
2.33 (m, 6H), 1.69–1.59 (m, 6H), 1.43–1.28 (m, 8H), 0.98–0.88 (m, 9H). 13C NMR 
(CDCl3, 100 MHz) δ: 180.7, 173.5, 172.9, 66.2, 63.7, 34.2, 34.1, 31.9, 29.2, 27.3, 27.1, 
24.9, 22.9, 22.6, 14.1, 14.1. (carbon signal next to diazo group might not show up) 
2-56 
3-diazo-4-oxodecane-1,2-diyl dihexanoate (2-56): 1H NMR (CDCl3, 400 MHz) δ: 
5.97–5.83 (m, 1H), 4.56–4.42 (m, 1H), 4.40–4.27 (m, 1H), 2.57–2.2.43 (m, 2H), 2.43–
2.28 (m, 6H), 1.73–1.57 (m, 6H), 1.40–1.26 (m, 12H), 0.97–0.86 (m, 9H). 13C NMR 
(CDCl3, 100 MHz) δ: 180.2, 173.5, 172.9, 66.2, 63.7, 34.4, 31.6, 24.9, 24.8, 22.9, 22.7, 
14.4, 14.3. (carbon signal next to diazo group might not show up) 
2-57 
3,4-dioxopentane-1,2-diyl diacetate (2-57): 1H NMR (CDCl3, 400 MHz) δ: 5.88–
5.83 (m, 1H), 4.72–4.64 (m, 1H), 4.40–4.32 (m, 1H), 2.39 (s, 3H), 2.18 (s, 3H), 2.06 
(s, 3H). 13C NMR (CDCl3, 100 MHz) δ: 196.3, 190.4, 171.5, 170.5, 62.7, 24.1, 21.0, 
20.7. Derivatization using 1,2-diaminobenzene MS (ESI): Calcd for [C15H16N2O4 + 
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H]+ 289.1188, found 289.1234. 
2-58 
3,4-dioxopentane-1,2-diyl dibutyrate (2-58): 1H NMR (CDCl3, 400 MHz) δ: 5.90–
5.84 (m, 1H), 4.75–4.66 (m, 1H), 4.41–4.32 (m, 1H), 2.46–2.40 (m, 2H), 2.39 (s, 3H), 
2.29 (t, J = 7.4 Hz, 2H), 1.73–1.66 (m, 2H), 1.66–1.58 (m, 2H), 0.99 (t, J = 7.4 Hz, 
3H), 0.94 (t, J = 7.4 Hz, 3H). 13C NMR (CDCl3, 100 MHz) δ: 196.3, 190.5, 174.1, 
173.1, 62.5, 36.1, 35.8, 24.1, 18.7, 18.6, 13.9. Derivatization using 1,2-
diaminobenzene MS (ESI): Calcd for [C19H24N2O4 + H]+ 345.1814, found 345.1809. 
2-59 
3,4-dioxopentane-1,2-diyl dipentanoate (2-59): 1H NMR (CDCl3, 400 MHz) δ: 
5.89–5.83 (m, 1H), 4.74–4.65 (m, 1H), 4.41–4.32 (m, 1H), 2.48–2.41 (m, 2H), 2.40 (s, 
3H), 2.34–2.28 (m, 2H), 1.70–1.61 (m, 2H), 1.61–1.53 (m, 2H), 1.44–1.30 (m, 4H), 
0.98–0.89 (m, 6H). 13C NMR (CDCl3, 100 MHz) δ: 196.3, 190.5, 174.3, 173.3, 62.5, 
34.0, 33.7, 27.2, 24.1, 22.5, 14.1, 14.0. Derivatization using 1,2-diaminobenzene MS 




3,4-dioxopentane-1,2-diyl dihexanoate (2-60): 1H NMR (CDCl3, 400 MHz) δ: 5.91–
5.82 (m, 1H), 4.75–4.64 (m, 1H), 4.42–4.30 (m, 1H), 2.47–2.40 (m, 2H), 2.39 (s, 3H), 
2.33–2.25 (m, 3H), 1.72–1.62 (m, 2H), 1.62–1.53 (m, 2H), 1.40–1.21 (m, 8H), 0.97–0.83 
(m, 6H). 13C NMR (CDCl3, 100 MHz) δ: 196.3, 190.5, 174.2, 173.3, 72.9, 62.5, 34.2, 33.9, 
31.5, 24.8, 24.1, 22.7, 22.6, 14.3. Derivatization using 1,2-diaminobenzene MS (ESI): 
Calcd for [C23H32N2O4 + H]+ 401.2440, found 401.2479. 
2-61 
6-methyl-3,4-dioxoheptane-1,2-diyl diacetate (2-61): 1H NMR (CDCl3, 400 MHz) 
δ: 5.89–5.83 (m, 1H), 4.70–4.61 (m, 1H), 4.45–4.36 (m, 1H), 2.78–2.58 (m, 2H), 2.23–
2.19 (m, 1H), 2.19 (s, 3H), 2.06 (s, 3H), 0.98 (d, J = 2.7 Hz, 3H), 0.97 (d, J = 2.7 Hz, 
3H). 13C NMR (CDCl3, 100 MHz) δ: 198.2, 191.0, 171.2, 170.4, 73.2, 62.7, 45.0, 24.4, 
22.9, 21.0, 20.7. Derivatization using 1,2-diaminobenzene MS (ESI): Calcd for 
[C18H22N2O4 + H]+ 331.1658, found 331.1740. 
2-62 
6-methyl-3,4-dioxoheptane-1,2-diyl dibutyrate (2-62): 1H NMR (CDCl3, 400 MHz) 
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δ: 5.89–5.82 (m, 1H), 4.70–4.62 (m, 1H), 4.46–4.37 (m, 1H), 2.77–2.58 (m, 2H), 2.46–
2.34 (m, 2H), 2.33–2.24 (m, 2H), 2.23–2.12 (m, 1H), 1.74–1.58 (m, 4H), 1.02–0.90 (m, 
12H). 13C NMR (CDCl3, 100 MHz) δ: 198.3, 191.1, 173.8, 173.1, 62.5, 45.0, 36.1, 
35.9, 24.4, 22.9, 22.8, 18.7, 18.6, 13.9. Derivatization using 1,2-diaminobenzene MS 
(ESI): Calcd for [C22H30N2O4 + H]+ 387.2284, found 387.2244. 
2-63 
6-methyl-3,4-dioxoheptane-1,2-diyl dipentanoate (2-63): 1H NMR (CDCl3, 400 
MHz) 5.89–5.82 (m, 1H), 4.70–4.61 (m, 1H), 4.46–4.37 (m, 1H), 2.78–2.58 (m, 2H), 
2.48–2.38 (m, 2H), 2.35–2.25 (m, 2H), 2.25–2.13 (m, 1H), 1.68–1.54 (m, 4H), 1.43–
1.30 (m, 4H), 1.01–0.89 (m, 12H). δ. 13C NMR (CDCl3, 100 MHz) δ: 198.3, 191.1, 
174.0, 173.3, 62.5, 45.0, 34.0, 27.2, 22.9, 22.5, 14.1, 14.0. Derivatization using 1,2-
diaminobenzene MS (ESI): Calcd for [C24H34N2O4 + H]+ 415.2597, found 415.2599. 
2-64 
6-methyl-3,4-dioxoheptane-1,2-diyl dihexanoate (2-64): 1H NMR (CDCl3, 400 
MHz) δ: 5.89–5.82 (m, 1H), 4.70–4.60 (m, 1H), 4.46–4.36 (m, 1H), 2.77–2.57 (m, 2H), 
2.33–2.25 (m, 2H), 2.23–2.12 (m, 1H), 1.70–1.54 (m, 4H), 1.39–1.25 (m, 8H), 1.02–
0.95 (m, 6H), 0.95–0.87 (m, 6H). 13C NMR (CDCl3, 100 MHz) δ: 198.3, 191.1, 174.0, 
173.3, 62.5, 34.2, 31.5, 24.8, 22.9, 22.7, 14.3. Derivatization using 1,2-diaminobenzene 
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MS (ESI): Calcd for [C26H38N2O4 + H]+ 443.2910, found 443.2855. 
2-65 
3,4-dioxodecane-1,2-diyl diacetate (2-65): 1H NMR (CDCl3, 400 MHz) δ: 5.90–5.84 
(m, 1H), 4.71–4.64 (m, 1H), 4.45–4.36 (m, 1H), 2.87–2.72 (m, 2H), 2.19 (s, 3H), 2.17 
(s, 3H), 1.68–1.58 (m, 2H), 1.38–1.27 (m, 6H), 0.94–0.87 (m, 3H). 13C NMR (CDCl3, 
100 MHz) δ: 198.7, 190.9, 171.2, 170.4, 73.2, 62.7, 36.5, 31.9, 29.1, 23.1, 22.9, 21.0, 
20.8, 14.4. Derivatization using 1,2-diaminobenzene MS (ESI): Calcd for [C20H26N2O4 
+ H]+ 359.1971, found 359.1963. 
2-66 
3,4-dioxodecane-1,2-diyl dibutyrate (2-66): 1H NMR (CDCl3, 400 MHz) δ: 5.91–
5.84 (m, 1H), 4.72–4.64 (m, 1H), 4.46–4.37 (m, 1H), 2.86–2.2.72 (m, 2H), 2.47–2.38 
(m, 2H), 2.33–2.24 (m, 2H), 1.76–1.1.60 (m, 6H), 1.38–1.27 (m, 6H), 1.04–0.88 (m, 
9H). 13C NMR (CDCl3, 100 MHz) δ: 198.7, 191.0, 173.9, 173.1, 73.1, 62.5, 36.5, 36.2, 
35.9, 31.9, 29.1, 23.1, 22.9, 18.7, 14.4, 14.0. Derivatization using 1,2-diaminobenzene 




3,4-dioxodecane-1,2-diyl dipentanoate (2-67): 1H NMR (CDCl3, 400 MHz) δ: 5.90–
5.83 (m, 1H), 4.71–4.63 (m, 1H), 4.45–4.37 (m, 1H), 2.85–2.72 (m, 2H), 2.48–2.40 (m, 
2H), 2.40–2.34 (m, 2H), 2.34–2.27 (m, 2H), 1.69–1.57 (m, 6H), 1.45–1.30 (m, 8H), 
0.97–0.89 (m, 9H). 13C NMR (CDCl3, 100 MHz) δ: 198.7, 191.0, 174.1, 173.3, 73.1, 
62.5, 36.5, 34.0, 33.8, 31.9, 29.1, 27.2, 23.1, 22.9, 22.6, 22.5, 14.4, 14.1. Derivatization 
using 1,2-diaminobenzene MS (ESI): Calcd for [C26H38N2O4 + H]+ 443.2910, found 
443.2867. 
2-68 
3,4-dioxodecane-1,2-diyl dihexanoate (2-68): 1H NMR (CDCl3, 400 MHz) δ: 5.90–
5.83 (m, 1H), 4.72–4.62 (m, 1H), 4.45–4.36 (m, 1H), 2.86–2.71 (m, 2H), 2.48–2.40 (m, 
2H), 2.40–2.33 (m, 2H), 2.33–2.25 (m, 2H), 1.71–1.58 (m, 6H), 1.39–1.27 (m, 12H), 
0.96–0.87 (m, 9H). 13C NMR (CDCl3, 100 MHz) δ: 198.7, 191.0, 174.1, 173.3, 73.1, 
62.5, 36.5, 34.3, 34.0, 31.9, 31.6, 31.5, 29.1, 24.8, 23.1, 22.9, 22.7, 14.4, 14.3. 
Derivatization using 1,2-diaminobenzene MS (ESI): Calcd for [C28H42N2O4 + H]+ 




Chapter 3. Geminal dihalogen isosteric replacement in hydrated AI-2 affords 
analogs that potently modulate quorum sensing 
3.1 Introduction 
AI-2 is probably the most complex and fascinating QS molecule described to 
date. It is produced by many bacterial strains and either the molecule itself or its 
synthase, LuxS, affect the physiology (including biofilm formation)42a, 113 of multitudes 
of bacteria, some of which are of clinical and bioterrorism relevance, such as Vibrio 
cholera,26a Yersinia pestis114 and Staphyloccocus aureus.70 AI-2 production as well as 
degradation affects central metabolism and emerging data suggests that it could be used 
as an alternative carbon source to produce acetyl-CoA.41, 115 From a chemical 
perspective, AI-2 shows remarkable diversity as a signaling molecule (see Figure 3-1 
for the possible inter-converting isomers of AI-2) and depending on environmental 
conditions, AI-2 can exhibit selectivity in QS signaling. For example, in the presence 
of boric acid (such as in aquatic environment), AI-2 predominantly forms the boronate 
ester (3-4, Figure 3-1), which is a ligand for LuxP of Vibrios.23 Enteric bacteria, such 
as E. coli and Salmonella use AI-2, only after it has been processed by LsrK kinase.111 
So far four different proteins have been characterized that bind to AI-2: LuxP, which 
binds to a boronated form (3-4);23 LsrB (a transporter), which binds to the cyclic but 
non-boronated form (3-6);39, 80 LsrR, which binds to the phosphorylated linear form 
(and with the 3-position as the hydrate, 7)81 and LsrF, which binds to the 1,3-diketo 




Figure 3-1. Chemical structures of AI-2. 
 
Figure 3-2. a) 3-hydrated DPD (3-7) and 3,3-dihalogen analogs that were planned to 
synthesize for this study. b) Degradation of AI-2 via LsrG/LsrF. We expect that the 
geminal dihalogen analogs cannot form the 1,3-diketone intermediate (3-10) hence 
would not be degraded by LsrG/LsrF. 
Due to the ubiquity of AI-2 in bacterial QS signaling, there is interest in 
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developing small molecules that can modulate AI-2-based signaling. Such anti-AI-2 
small molecules could be used in synergy with traditional antibiotics116 or as tools in 
synthetic biology to modulate systems that use AI-2-based circuits.84c A fruitful 
approach to develop anti-AI-2 molecules have been the modification of AI-2 at the 
C1,83, 84c, d, 107a C4107a, 117 or C5-positions87 into analogs that have shown great promise 
as either antibiofilm or synergistic antibacterial agents.116 Recently, we disclosed that 
LsrR, the response regulator that binds to phosphorylated AI-2 to modulate many genes 
actually bound to the 3,3-hydrated form of AI-2 (3-7, Figure 3-1).81 We rationalized 
that isosteric replacement at the C3 position of AI-2 could prevent isomerization into 
the 1,3-diketo analog (3-10), which is a substrate for LsrF degradation (see Figure 3-
2b).41  
 
Figure 3-3. Phospho-AI-2 in its hydrated form at C3 when binding with LsrR (PDB code: 4L4Z). 
Analysis of interactions between P-AI-2 (phospho-3-hydrated DPD) and active-
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site residues in LsrR indicated that Asp243 was within 3Å of the geminal diol unit of 
AI-2 (see Figure 3-3), indicating that if Asp243 existed as the carboxylate form, then 
the hydrogens of the geminal diol could potentially form hydrogen-bonding 
interactions with this residue. A geminal bromide or chloride, but not fluoride, could 
recapitulate this interaction via the halogen bond (strength of halogen bond is as follows: 
I >Br>Cl>>F).118 On the other hand, if the Asp243 is protonated in the active site, then 
it is conceivable that the carbonyl moiety could still partake in a halogen bond 
interaction with one of the geminal halogens whereas the carboxylic acid OH group 
would act as a hydrogen bond donor to the halogen.119 It is the ambivalence of higher 
halogens (presence of lone pairs for hydrogen bond formation and presence of a low 
lying σ*C-X bond for halogen bond formation, see Figure 3-4)120 that makes them ideal 




Figure 3-4. Postulated binding mode of AI-2 and dihalogenated AI-2 with Asp-243. a) 
carboxylic acid as hydrogen donor to form hydrogen bond with one of the hydroxyl 
groups on P-AI-2. b) one of the hydroxyl groups on P-AI-2 as hydrogen donor to form 
hydrogen bond with carboxylate. Halogens partaking in hydrogen bonding c) and 
halogen bonding d). 
3.2 Results and discussion 
Attempted synthesis of targeted dihalogen compounds 3-15 to 3-20 was fraught with 
difficulties because the final products were volatile (see Scheme 3-1). Others and us 
have, however, demonstrated that ester prodrug versions of AI-2 are convenient sources 
of AI-2 because the esters can be easily purified on column chromatography and used 
directly in QS assays without prior deprotection of the esters.85-86 Presumably, esterases 
produced by bacteria hydrolyze the esters into the active compounds, obviating a need 
for ester unmasking. Therefore we proceeded to make the ester “pro-drug” versions of 
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compounds 3-15 to 3-20 as 3-34 to 3-39. The propyl ester was chosen as we rationalized 
that perhaps the shorter methyl and ethyl esters would have volatility issues whereas 
the longer chains, greater than propyl, might be hydrolyzed slowly. This decision was 
just based on our intuition and not by any hard facts. Target compounds, 3-34 to 3-39 
were synthesized using strategies shown in Scheme 3-2. 
 
Scheme 3-1. Initial attempt to make dichloro AI-2 3-17. 
 




Figure 3-5. OD600 value of E. coli LW7 (luxS-) after 24 hrs growth at different conditions: E. coli 
LW7 (luxS-) alone; and E. coli LW7 (luxS-) in the presence of 100 μM of each analog, respectively. 
With these molecules in hand, we investigated if they were non-toxic and could 
modulate quorum sensing in E. coli. Pleasingly, at 100 µM concentration, all of the 
compounds were non-toxic towards E. coli (see Figure 3-5). Using the E. coli strain 
LW7 (LuxS- and harboring the β-gal gene), we could use the β-galactosidase assay to 
evaluate our analogs.84c, d The β-gal gene in LW7 is under the control of the LsrR 
repressor. At high concentration of P-AI-2, the ligand binds to LsrR to dissociate it 
from the LsrR promoter region and therefore permit the transcription of the genes under 
the control of the LsrR repressor.40 We have previously reported that the size of the C1 
alkyl group of AI-2 and analogs determines whether an analog would be an LsrR 
agonist or antagonist.84d Recently a rationale for this observation was provided via the 
crystal structure of LsrR in complex with AI-2 or analogs.81 Based on the LsrR crystal 














agonists whereas the isobutyl dihalogen analogs would be antagonists, as long as the 
isosteric replacement of the geminal hydroxyl group with halogens does not adversely 
affect binding of the ligand to LsrR. Interestingly dibromo-AI-2 (3-38) and dichloro-
AI-2 (3-36), but not difluoro-AI-2 (3-34), could induce β-gal transcription (analyzed 
via the β-galactosidase assay), see Figure 3-6a. In the absence of AI-2, the level of β-
galactosidase is low, whereas when 20 µM of AI-2 or dibromo-AI-2 (3-38) or dichloro-
AI-2 were added (3-36) to LW7, the level of β-galactosidase increased (see activity 
assay in Figure 3-6a). The dibromo analog of AI-2 (3-38) was as potent as AI-2, the 
activity of the dichloro-AI-2 (3-36) was slightly lower than the native AI-2 molecule. 
In line with our expectation, none of the isobutyl dihalogen analogs were LsrR 
agaonists, augmenting earlier observations that longer C1 chain AI-2 analogs are not 




Figure 3-6. a) AI-2 dependent β-galactosidase production of E. coli LW7 (luxS-) in 
response to 20 μM synthetic AI-2 or analogs. 100% native E. coli LW7 (luxS-) + AI-2 
response = 167 Miller units. b) Analogs (20 μM) inhibit native β-galactosidase 
production in E. coli LW7 (luxS-) in the presensce of 20 μM synthetic AI-2. 100% 
native E. coli LW7 (luxS-) + AI-2 response = 486 Miller units. (With the help of Yue 
Zheng, a graduate student from the Sintim group). 
Isobutyl AI-2 (3-14) is a potent inhibitor of AI-2 signaling, via LsrR binding,81, 
84c, d and has been shown to inhibit E. coli biofilm formation, either alone or in 
combination with traditional antibiotics, such as gentamicin.116 In fact isobutyl AI-2 (3-
14) has a higher affinity for LsrR than AI-2; the dissociation constant, Kd, of AI-2/LsrR 
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complex is 2.0 µM whereas isobutyl-AI-2/LsrR has a Kd of 0.5 µM. Since the dichloro 
and dibromo mimics of AI-2 (3-36, 3-38) were potent LsrR agonists, we wondered if 
the isobutyl-dihalogens would also be potent antagonists of LsrR. Interestingly both 
isobutyl dibromo and dichloro analogs of AI-2 were antagonists of LsrR (see Figure 
3-6b). Whereas in the absence of these ligands 20 µM AI-2 could induce β-gal 
expression, when equimolar amounts of isobutyl dibromo (3-39) or dichloro AI-2 (3-
37) were added, these could compete with AI-2 and prevent β-gal expression above the 
background, see Figure 3-6b. Here too the isobutyl difluoro analog (3-35) was not an 
effective antagonist.  
Next, we examined the effects of our analogs on E. coli W3110 pCT6 (luxS+), 
which contains an egfp gene under LsrR control. Because W3110 pCT6 can make its 
own AI-2, in the absence of any AI-2 antagonist, about 90% of the population 
expressed the EGFP protein, see Figure 3-7. The addition of the dihalogenated isobutyl 
DPD analogs caused a reduction of the EGFP expression. In agreement with the β-gal 
assay (Figure 3-7), dibromo-iBu-AI-2 (3-36) was a better inhibitor than dichloro-iBu-




Figure 3-7. AI-2 dependent EGFP induction in E.coli W3110 pCT6(luxS+) in response 
to difluoro-i-Bu-AI-2 (3-35), dichloro-i-Bu-AI-2 (3-37) and dibromo-i-Bu-AI-2 (3-39) 
(FACS analysis with microscopic image). (Done by Jessica L. Terell, from the Bentley 
laboratory).  
To explain our observations that the dibromo analog was a better mimic of hydrated 
AI-2 than the dichloro analog, which was also better than the difluoro analog, we 
compared the size (sterics) and electronics of the geminal dihydroxyl moiety with the 
various dihalogens in the cyclized and linear analog forms (see Figures 3-8 and Table 
3-1). The space-filling models of AI-2 and its halogenated analogs (Figures 3-8) 
revealed that the fluoro analog (3-15) was smaller in size compared with AI-2 DPD (3-
7) while both the chloro and bromo analogs, (3-17) and (3-19), were bigger than AI-2 




   3-7       3-15               3-17            3-19 
 
 cyclic 3-7       cyclic 3-15      cyclic 3-17       cyclic 3-19 
Figure 3-8. Structures of AI-2 and its halogenated analogs with varied shapes and sizes. 










-OH 3-7  150.13 120.33 1.40 4.24 
-F 3-15 154.11 115.08 1.37 3.20 
-Cl 3-17 187.02 137.98 1.81 3.02 
-Br 3-19 275.92 149.46 2.00 2.97 
-OH Cyclic 3-7 150.13 118.14 1.41 4.23 
-F Cyclic 3-15 154.11 110.84 1.38 3.02 
-Cl Cyclic 3-17 187.02 132.77 1.80 3.30 
-Br Cyclic 3-19 275.92 144.87 1.96 3.12 
Table 3-1. Comparison of properties of AI-2 and analogs. 
   
Apart from size, electronics could also play an important role in ligand-receptor binding. 
Electrostatic potential surfaces for AI-2 and analogs (Figure 3-9), in both linear and 
cyclic forms were calculated using Gaussian 09121 at B3LYP/6-31G(d) level with 
solvent effect (water, PCM model). For chloro- and bromo- analogs, in both linear and 
cyclized forms, there is a region of positive potential at the opposite end of the C-X 
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bond (on the halogen side). This positive region is called σ-hole, which is the basis of 
halogen bonding. So we speculate that chloro and bromo moieties in our analogs could 
function as electrophiles and partake in halogen bonding. Therefore even in the absence 
of hydroxyl groups, they could still interact with aspartic acid 243 in LsrR (see Figure 
3-9). In the case of difluoro analogs, neither the size of fluoro moiety nor the electronics 
mimic the hydroxyl group well and hence the lack of activity (agonism or antagonism) 
seen with the difluoro substitution.  
 
Figure 3-9. Molecular surface electrostatic potential of AI-2 and analogs in simplified 
models. Color ranges from -9.5 kcal/mol (red) to 9.5 kcal/mol (blue). Important atoms 





In conclusion, we have designed and prepared a new generation of AI-2 analogs 
with dihalogen at C3 position. This set of analogs exhibited similar bioactivities with 
our earlier generation of analogs with modified C1 but intact C3 but has the added 
advantage that isomerization into a 1,3-diketo, which facilitates LsrF degradation, is 
not possible. This work demonstrates that geminal dihalogens, especially of higher 
halogens, are good mimics of hydrated moieties in biological ligands. It is expected 
that the substitution of geminal hydroxyl groups with dihalogen would afford 
molecules that could cross cell membranes more easily. Also for ligands whereby the 
hydrated form or keto form could facilitate degradation, such as in AI-2, isosteric 
replacement with dihalogens would provide more stable analogs.  
3.4 Detailed experimental procedures and characterizations 
Bioassay procedures 
β-galactosidase assay: Grew E. coli ZK126 (Wild-type strain derivative, W3110 
ΔlacU160-tna2) and LW7 (ZK126 ΔluxS) with ampicillin overnight. Diluted the 
overnight culture 40 times and grew at 37 °C until OD600 reached 0.8. Spin down the 
cells and resuspend the cell pellets in PBS. Made 500 μL aliquots, added the AI-2 
analogs and grew the bacteria at 37 °C for 2 hours. Spin down the cells and resuspend 
the cell pellets in 500 μL Z-buffer. Use 250 μL of cell suspension for OD600 
measurement. The rest of cell suspension (250 μL) was mixed with 25 μl of CH3Cl and 
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12.5 μL of 0.1% SDS and incubated at room temperature for 5 min. After adding 50 μL 
of ONPG (4 mg/mL in Z-buffer), samples were incubated at 28 °C for 40 min. 125 μL 
of 1 M sodium carbonate solution was used to stop reaction. Centrifuged at 4 °C for 5 
min and took 250 μl supernatant for OD420 and OD550 measurement. Optical density 
was measured by Molecular Devices SpectraMax M5e microplate reader. (With the help 
of Yue Zheng, a graduate student from the Sintim group). 
β-galactosidase units was calculated using the following equation: 
β-galactosidase units=1000 x (OD420 – (1.75 x OD550) / (0.25 (ml) x 40 (min) x OD600)) 
Flow cytometry assay: E.coli W3110 pCT6122 + pET200-EGFP-Lys123 was cultured  
from colony in Luria-Bertani medium supplemented with ampicillin and kanamycin. 
At OD600 0.1, cultures were supplemented with 20 μM of the AI-2 analog (or an 
equivalent volume of DMSO for negative controls) and incubated in triplicate for 6 h 
at 37 °C with shaking (250 rpm). The E.coli green fluorescence response was 
determined using fluorescence microscopy (Olympus BX60) and flow cytometric 
analysis. Samples were analyzed by flow cytometery (FACS CantoII, BD 394 
Biosciences), using a 488 nm laser and 530/30 filter set with 50000 gated events 
analyzed per sample. (Done by Jessica L. Terell, from the Bentley laboratory).  
Chemical synthesis procedures and characterization of new compounds  
All reagents were obtained commercially unless otherwise noted. Reactions were 
performed using oven-dried glassware under an atmosphere of argon. Air- and 
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moisture-sensitive liquids and solutions were transferred via syringe or stainless steel 
cannula. Dry tetrahydrofuran (THF) and diethyl ether (Et2O) were distilled over sodium 
prior to use and dry dichloromethane (DCM) was distilled over CaH2 prior to use. Thin-
layer chromatography (TLC) was performed on Merck Kieselgel 60 F254 plates. 
Visualization of the developed chromatogram was accomplished by UV light or by 
staining with KMnO4 solution. Chromatographic purification of products was 
accomplished using flash column chromatography on silica gel (230 X 400 mesh) or 
GRACE Reveleris® X2 flash Chromatography system with Reveleris® flash cartridges 
(40 µM silica). Compounds purified by chromatography on silica gel were typically 
applied to the absorbent bed using the indicated solvents conditions with a minimum 
amount of added dichloromethane as needed for solubility. Solvents were removed 
from the reaction mixture or combined organic extracts by concentration under reduced 
pressure using an evaporator with bath at 30–40 . Elevated temperatures were obtained 
using thermostat-controlled silicone oil baths. Low temperatures were obtained by ice 
bath or by mixing dry-ice with organic solvents. NMR spectra were measured on 
Bruker AV-400, Bruker DRX-400 (1H at 400 MHz, 13C at 100MHz), Bruker DRX-500 
(1H at 500 MHz, 13C at 125MHz) or Bruker AVIII-600 (1H at 600 MHz, 13C at 150MHz). 
Data for 1H -NMR spectra are reported as follows: chemical shift (ppm, relative to 
residual solvent peaks or indicated external standards; s = singlet, d = doublet, t = triplet, 
q = quartet, dd = doublet of doublets, td = triplet of doublets, m = multiplet), coupling 
constant (Hz), and integration. Data for 13C -NMR are reported in terms of chemical 
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shift (ppm) relative to residual solvent peak. Mass spectra (MS) and high resolution 
mass spectra (HRMS) were recorded by JEOL AccuTOF-CS (ESI positive, needle 
voltage 1800~2400 eV). Infrared spectra (IR) were recorded by a ThermoNicolet 
IR200 Spectrometer.  
Initial attempt to make dichloro AI-2 3-17: 
Refer to Scheme 3-1. 
To a stirred suspension of tBuOK (6 mg, 0.1 equiv) in anhydrous THF was 
added 1,1-dichloro-2-propanone 3-23 (50 µL, 0.50 mmol), followed by 
benzyloxyacetaldehyde 3-24 (70 µL, 1.0 equiv) at -78 oC under argon. The reaction 
was allowed to warm up to room temperature gradually and stirred overnight. Then the 
reaction was quenched by saturated NH4Cl (aq) carefully at 0 oC. The organic layer was 
separated and the aqueous layer was extracted with EtOAc three times. The combined 
organic phase was dried over MgSO4.  The product was purified by silica column 
chromatography (EtOAc: Hexanes = 1: 8, v/v) and 3-25 was obtained as 93 mg clear 
oil (67 % yield). To make dichloro AI-2 3-17, 3-25 (39 mg, 0.14 mmol) was dissolved 
in 2 mL methanol, which was suspended with Pd/C (5% on carbon, 29 mg, 10 mol%). 
The reaction flask was vacuumed and then charged by H2 balloon. The reaction was 
stirred at room temperature overnight. Then Pd/C was filtered and the filtrate was 
evaporated at reduced pressure. However, the product 3-17 was volatile and left the 




5-(benzyloxy)-3,3-dichloro-4-hydroxypentan-2-one (3-25):  
3-25 was obtained as 93 mg clear oil (67 % yield). 1H NMR (400 MHz, CDCl3) δ ppm 
= 7.42-7.30 (5H, m), 4.65-4.58 (2H, m), 4.58-4.51 (1H, m), 3.98-3.90 (1H, m), 3.81-
3.73 (1H, m), 3.23 (1H, d, J = 5.2 Hz), 2.52 (3H, s). 13C NMR (100 MHz, CDCl3) δ 
ppm = 196.4, 137.8, 128.9, 128.4, 128.2, 89.0, 75.4, 74.0, 70.4, 24.8. HRMS (ESI+) 
m/z calcd. for C12H15Cl2O3 [M+H]+ 277.0398, found 277.0422. 
Synthesis of the starting materials for dihalogen AI-2 analogs: 
 
 
1,1-dichloro-4-methylpentan-2-one (3-31):  
The synthesis was similar to the reference.124 Generally, to a stirred solution of 
dichloromethane (10 mmol, 0.64 ml) and ethyl isovalerate S3 (5 mmol, 0.75 ml) in 
anhydrous THF (10 ml), was added a solution of lithium dicyclohexylamide in 10 ml 
anhydrous THF over 10 min at -78  under argon. The resulting mixture was stirred 
for another 20 min at -78  and then carefully quenched with 6 M HCl (aq). The 
reaction was allowed to warm up slowly and then the white precipitate was filtered off. 
The filtrate was extracted with Et2O (5ml x 3) and organic layer was dried with MgSO4. 
The solvent was carefully removed in vacuo to avoid the loss of volatile product 28. 
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The product was obtained as 0.75 g slightly yellow liquid (89% yield) and used for the 
next step without purification. 
 
The starting diazocarbonyls S4 and S5 were obtained using the same method reported 
by our group.86 To a stirred solution of the diazocarbonyl (3 mmol) in anhydrous DCM 
(10 ml) was added a solution Br2 (1.2 equiv, 0.18 ml) in in anhydrous DCM (5 ml) 
dropwise at -78 oC. The resulting solution was allowed to warm up to room temperature 
in 1 hr and then the reaction was quenched by saturated NaHSO3 (aq). The organic 
layer was separated and dried with MgSO4. The solvent was carefully removed in 
vacuo to avoid the loss of volatile product 29/30. The yield was quantitative and if 
necessary, the product could be purified by a short column with hexanes. 
The synthesis was similar to the reference.125 Generally, To a solution of 2,2-
dimethoxyethanol 3-43 (5 mmol, 0.51 ml), DMAP (catalytic) and dry Et3N (1.1 equiv, 
0.71 ml) in anhydrous DCM, was added butyryl chloride 3-44 (1 equiv, 0.50 ml) 
dropwise at 0 oC under argon. The reaction was allowed to warm up to room 
temperature and stirred overnight. The resulting solution was washed with saturated 
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NaHCO3 (aq) and brine, then dried with MgSO4. The solvent was removed at reduced 
pressure and the product 3-45 was obtained as clear oil at quantitative yield without 
further purification.  
A well-stirred solution of 3-45 (5 mmol) in DCM (25 ml) was treated with TFA (9.75 
equiv, 3.8 ml) and water (10 equiv, 0.9 ml) at room temperature. After stirring for 5 hr, 
the solution was evaporated and the crude product was purified by flash silica 
chromatography (EtOAc: Hexanes = 1: 2, v/v). The product 3-29 was obtained as clear 
thick oil (560 mg, 86% yield). 
Synthesis of difluoro AI-2 analogs: 
Refer to Scheme 3-2. 
The synthesis was similar to the reference.126 Generally, a solution of corresponding 
Grignard reagent (2M in Et2O, 30 mmol) was slowly added a solution of 
chlorodifluoroacetic acid 3-26 (10 mmol, 0.84 ml) in anhydrous diethyl ether at -20 oC 
under argon. The resulting mixture was kept stirring for another 12 hr. Then the reaction 
mixture was hydrolyzed with 6M HCl (aq) below 0 oC and stirred for 1 hr at room 
temperature. The resuting mixture was extracted with diethyl ether (10 ml x 3) and the 
combined organic layer was washed with saturated NaHCO3 (aq) and brine, then dried 
with MgSO4 and finally concentrated in mild vacuum to avoid the loss of volatile 
product 3-27/3-28. Products were obtained in high yield without further purification.  
Acid-activated Zn powder (3 equiv, 149 mg) and CuI (0.1 equiv, 8 mg) were suspended 
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in anhydrous THF and stirred for 0.5 hr at room temperature under argon. To the 
resulting mixture was added a solution of corresponding chlorodifluoromethyl ketone 
3-27/3-28 (100 mg, 0.76 mmol) and 3-29 in anhydrous THF. The mixture was refluxed 
for 4 hr and then cooled down to room temperature. The reaction mixture was then 
filtered with Celite and the filtrate was concentrated under vacuum. The products of 
difluoro AI-2 analogs 3-34/3-35 were purified by flash silica chromatography (EtOAc: 
Hexanes = 1: 6, v/v). 
 
3,3-difluoro-2-hydroxy-4-oxopentyl butyrate (3-34): 
3-34 was obtained as 60 mg clear oil (35 % yield). 1H NMR (500 MHz, CDCl3) δ ppm 
= 4.45-4.26 (3H, m), 3.00-2.92 (1H, m), 2.45-2.40 (3H, m), 2.37 (2H, t, J = 7.4 Hz), 
1.74-1.65 (2H, m), 0.99 (3H, t, J = 7.4 Hz). 13C NMR (125 MHz, CDCl3) δ ppm = 
198.8 (t, J = 31.2 Hz), 174.0, 114.4 (t, J = 253.8 Hz), 69.9 (m), 62.7, 35.8, 25.2, 18.2, 
13.5. 19F NMR (376 MHz, CDCl3) δ ppm = -113.54 (1F, dd, J = 279.2, 6.4 Hz), -123.21 
(1F, dd, J = 280.7, 15.6 Hz). HRMS (ESI+) m/z calcd. for C9H15F2O4 [M+H]+ 225.0938, 
found 225.0923. 
 
3,3-difluoro-2-hydroxy-6-methyl-4-oxoheptyl butyrate (3-35): 
3-35 was obtained as 93 mg clear oil (67 % yield). 1H NMR (400 MHz, CD2Cl2) δ ppm 
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= 4.41-4.26 (3H, m), 3.14-3.02 (1H, m), 2.64 (2H, d, J = 6.7 Hz), 2.36 (2H, t, J = 7.4 
Hz), 2.27-2.16 (1H, m), 1.74-1.60 (2H, m), 1.02-0.90 (9H, m). 13C NMR (125 MHz, 
CD2Cl2) δ ppm = 200.6 (t, J = 27.5 Hz), 173.8, 114.7 (t, J = 255.0 Hz), 69.8 (t, J = 27.5 
Hz), 62.6, 46.2, 35.7, 23.4, 22.0, 18.2, 13.2. 19F NMR (376 MHz, CD2Cl2) δ ppm = -
114.30 (1F, dd, J = 276.3, 6.3 Hz), -124.34 (1F, dd, J = 275.5, 17.7 Hz). HRMS (ESI+) 
m/z calcd. for C12H24F2NO4 [M+NH4]+ 284.1673, found 284.1690. 
Synthesis of dichloro and dibromo AI-2 analogs: 
Refer to Scheme 3-2. 
Generally, to a stirred suspension of tBuOK (0.1 equiv) in anhydrous THF was added 
a solution of corresponding dihalogen ketone (1 equiv) and 3-29 (1 equiv) in anhydrous 
THF at -78oC under argon. The reaction was allowed to warm up to room temperature 
gradually and stirred overnight. Then the reaction was quenched by saturated NH4Cl 
(aq) carefully at 0 oC. The organic layer was separated and the aqueous layer was 
extracted with EtOAc three times. The combined organic phase was dried over MgSO4.  




3,3-dichloro-2-hydroxy-4-oxopentyl butyrate (3-36): 
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3-36 was obtained as 51 mg clear oil (64% yield). 1H NMR (400 MHz, CDCl3) δ ppm 
= 4.63-4.52 (2H, m), 4.47-4.35 (1H, m), 3.23 (1H, s, br), 2.57 (3H, s), 2.37 (2H, t, J = 
7.4 Hz), 1.74-1.65 (2H, m), 0.98 (3H, t, J = 7.4 Hz). 13C NMR (100 MHz, CDCl3) δ 
ppm = 196.7, 174.2, 87.4, 74.7, 64.7, 36.4, 24.2, 18.7, 14.0. HRMS (ESI+) m/z calcd. 
for C9H15Cl2O4 [M+H]+ 257.0347, found 257.0340. 
 
3,3-dichloro-2-hydroxy-6-methyl-4-oxoheptyl butyrate (3-37): 
3-37 was obtained as 74 mg clear oil (61% yield). 1H NMR (400 MHz, CDCl3) δ ppm 
= 4.62-4.51 (2H, m), 4.44-4.34 (1H, m), 3.22 (1H, s, br), 2.87-2.73 (2H, m), 2.36 (2H, 
t, J = 7.4 Hz), 2.29-2.18 (1H, m), 1.75-1.61 (2H, m), 1.03-0.86 (9H, m). 13C NMR (100 
MHz, CDCl3) δ ppm = 198.6, 174.2, 87.6, 74.7, 64.8, 45.0, 36.4, 25.0, 22.7, 22.5, 18.7, 
14.0. HRMS (ESI+) m/z calcd. for C12H21Cl2O4 [M+H]+ 299.0817, found 299.0821. 
 
3,3-dibromo-2-hydroxy-4-oxopentyl butyrate (3-38): 
3-38 was obtained as 74 mg clear oil (61% yield). 1H NMR (400 MHz, CDCl3) δ ppm 
= 4.75-4.65 (1H, m), 4.48-4.36 (2H, m), 3.37 (1H, s, br), 2.72 (3H, s), 2.38 (2H, t, J = 
7.4 Hz), 1.77-1.62 (2H, m), 0.98 (3H, t, J = 7.4 Hz). 13C NMR (100 MHz, CDCl3) δ 
ppm = 196.9, 174.2, 75.0, 69.4, 66.5, 36.4, 24.8, 18.8, 14.1. HRMS (ESI+) m/z calcd. 




3,3-dibromo-2-hydroxy-6-methyl-4-oxoheptyl butyrate (3-39): 
3-39 was obtained as 53 mg clear oil (40% yield). 1H NMR (400 MHz, CDCl3) δ ppm 
= 4.73-4.64 (1H, m), 4.50-4.34 (2H, m), 3.38 (1H, s, br), 3.05-2.92 (2H, m), 2.37 (2H, 
d, J = 7.4 Hz), 2.32-2.18 (1H, m), 1.76-1.62 (2H, m), 1.04-0.90 (9H, m). 13C NMR (100 
MHz, CDCl3) δ ppm = 198.7, 174.2, 75.0, 70.1, 66.6, 45.5, 36.4, 25.4, 22.7, 22.5, 18.8, 
14.1. HRMS (ESI+) m/z calcd. for C12H21Br2O4 [M+H]+ 388.9786, found 388.9804. 
Gaussian calculation results 
All the structures interested were optimized at B3LYP/6-31g(d) level using Gaussian 
09.121 A polarizable continuum model (PCM) was used as the SCRF method when 
solvation effect (water) is considered.  
 
Total energy of the optimized structure: -572.6433216 a.u.  
Number of imaginary frequencies: 0   
Cartesian Coordinates: 
--------------------------------------------------------------------- 
 Center     Atomic      Atomic             Coordinates (Angstroms) 
 Number     Number       Type             X           Y           Z 
 --------------------------------------------------------------------- 
      1          6           0       -1.203529    1.564230    0.149776 
      2          6           0       -1.161643    0.160716   -0.438110 
      3          6           0       -0.005068   -0.722572    0.100486 
      4          6           0        1.400010   -0.177156   -0.262557 
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      5          8           0       -0.096917   -0.865156    1.492751 
      6          8           0       -0.219802   -1.970875   -0.552828 
      7          6           0        2.294892    0.311235    0.848482 
      8          8           0       -0.041320    2.259358   -0.289077 
      9          8           0       -2.382792   -0.468146   -0.058650 
     10          8           0        1.740320   -0.195874   -1.431677 
     11          1           0       -2.123157    2.055491   -0.196962 
     12          1           0       -1.245344    1.495284    1.244615 
     13          1           0       -1.060350    0.218349   -1.529707 
     14          1           0       -1.045966   -1.005460    1.677626 
     15          1           0        0.303079   -2.638782   -0.077017 
     16          1           0        2.501349   -0.504452    1.550804 
     17          1           0        3.230649    0.681825    0.424713 
     18          1           0        1.796520    1.103835    1.413455 
     19          1           0        0.028204    3.076979    0.227259 
     20          1           0       -2.328862   -1.376244   -0.407391 
 --------------------------------------------------------------------- 
 
 Total energy of the optimized structure: -620.6888831 a.u.  
Number of imaginary frequencies: 0   
Cartesian Coordinates: 
--------------------------------------------------------------------- 
 Center     Atomic     Atomic              Coordinates (Angstroms) 
 Number     Number      Type              X           Y           Z 
 --------------------------------------------------------------------- 
    1          6             0       -1.346482    1.469234    0.095975 
    2          6             0       -1.207153    0.049106   -0.441618 
    3          6             0        0.023638   -0.658602    0.150399 
    4          6             0        1.391942   -0.129531   -0.339161 
    5          9             0       -0.029149   -0.629865    1.522739 
    6          9             0       -0.037706   -1.989216   -0.213513 
    7          6             0        2.366908    0.362356    0.695577 
    8          8             0       -0.146697    2.167660   -0.211813 
    9          8             0       -2.386246   -0.644003   -0.087201 
   10          8             0        1.626179   -0.191043   -1.531376 
   11          1             0       -2.223879    1.935318   -0.374371 
   12          1             0       -1.524820    1.417874    1.178452 
   13          1             0       -1.056847    0.076518   -1.531676 
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   14          1             0        1.914263    1.163519    1.286625 
   15          1             0        2.619911   -0.451594    1.386549 
   16          1             0        3.271817    0.721816    0.201636 
   17          1             0       -0.097665    2.971629    0.353566 




Total energy of the optimized structure: -1341.3842177 a.u.  
Number of imaginary frequencies: 0   
Cartesian Coordinates: 
--------------------------------------------------------------------- 
 Center     Atomic      Atomic             Coordinates (Angstroms) 
 Number     Number       Type             X           Y           Z 
 --------------------------------------------------------------------- 
      1          6           0       -1.509572   -1.629098   -0.132275 
      2          6           0       -0.118003   -1.222030   -0.619205 
      3          6           0        0.373100    0.105392    0.035867 
      4          6           0       -0.433153    1.338889   -0.497858 
      5         17           0        0.372099   -0.031032    1.838856 
      6         17           0        2.102776    0.386759   -0.498432 
      7          6           0       -1.008332    2.336402    0.469335 
      8          8           0       -2.378142   -0.509965   -0.252873 
      9          8           0        0.722786   -2.314220   -0.335751 
     10          8           0       -0.518052    1.447105   -1.703506 
     11          1           0       -1.846287   -2.472145   -0.749944 
     12          1           0       -1.430706   -1.975577    0.904948 
     13          1           0       -0.153612   -1.000555   -1.692768 
     14          1           0       -0.218851    2.767995    1.094143 
     15          1           0       -1.502809    3.125154   -0.100107 
     16          1           0       -1.725323    1.847404    1.133977 
     17          1           0       -3.166894   -0.681044    0.284235 






Total energy of the optimized structure: -5564.4100094 a.u.  
Number of imaginary frequencies: 0   
Cartesian Coordinates: 
--------------------------------------------------------------------- 
 Center     Atomic      Atomic             Coordinates (Angstroms) 
 Number     Number       Type             X           Y           Z 
 --------------------------------------------------------------------- 
      1          6           0        2.035562    0.054599    1.542411 
      2          6           0        0.517330    0.237038    1.489021 
      3          6           0       -0.032182    0.180165    0.036869 
      4          6           0        0.366362    1.432359   -0.801828 
      5         35           0        0.431872   -1.537737   -0.806352 
      6         35           0       -2.029613    0.251211    0.152736 
      7          6           0        0.966670    1.261472   -2.170320 
      8          8           0        2.631874    0.978000    0.641148 
      9          8           0       -0.017420   -0.768165    2.315697 
     10          8           0        0.134985    2.515756   -0.303900 
     11          1           0        2.357583    0.230312    2.577443 
     12          1           0        2.273233   -0.982722    1.279610 
     13          1           0        0.257100    1.242230    1.845845 
     14          1           0        0.278583    0.714053   -2.823663 
     15          1           0        1.168374    2.249333   -2.587656 
     16          1           0        1.890857    0.680882   -2.109611 
     17          1           0        3.550870    0.705224    0.496017 




Total energy of the optimized structure: -572.6508389 a.u.  
Number of imaginary frequencies: 0   
Cartesian Coordinates: 
--------------------------------------------------------------------- 
 Center     Atomic      Atomic             Coordinates (Angstroms) 




      1          6           0       -1.252736    0.371585   -0.564494 
      2          6           0       -0.714961    1.682871   -0.003230 
      3          8           0        0.705692    1.554326   -0.077756 
      4          6           0        1.117464    0.174041    0.050210 
      5          6           0       -0.226147   -0.638777   -0.017305 
      6          8           0       -2.560420    0.112147   -0.068078 
      7          8           0        1.785650   -0.036243    1.264458 
      8          6           0        2.101118   -0.113585   -1.072897 
      9          8           0       -0.203990   -1.773715   -0.844579 
     10          8           0       -0.577499   -0.975958    1.306682 
     11          1           0       -1.230942    0.366245   -1.659131 
     12          1           0       -1.010663    2.560262   -0.583638 
     13          1           0       -1.059673    1.810764    1.033441 
     14          1           0       -2.964132   -0.570731   -0.629002 
     15          1           0        1.088633   -0.182992    1.931715 
     16          1           0        1.633528    0.040827   -2.048096 
     17          1           0        2.951701    0.568445   -0.977535 
     18          1           0        2.467919   -1.141848   -1.014211 
     19          1           0        0.333833   -2.449665   -0.397246 




Total energy of the optimized structure: -620.6812635 a.u.  
Number of imaginary frequencies: 0   
Cartesian Coordinates: 
--------------------------------------------------------------------- 
 Center     Atomic      Atomic             Coordinates (Angstroms) 
 Number     Number       Type             X           Y           Z 
 --------------------------------------------------------------------- 
      1          6           0       -1.285222    0.335658   -0.523979 
      2          6           0       -0.782180    1.644092    0.083722 
      3          8           0        0.649086    1.559890    0.017300 
      4          6           0        1.105689    0.195288    0.022409 
      5          6           0       -0.216395   -0.626655   -0.000121 
      6          8           0       -2.597773    0.057114   -0.099300 
      7          8           0        1.870682   -0.079134    1.160378 
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      8          6           0        1.996579   -0.033362   -1.188501 
      9          1           0       -1.201798    0.368128   -1.618249 
     10          1           0       -1.098773    2.529391   -0.471318 
     11          1           0       -1.132097    1.726127    1.121967 
     12          1           0       -2.940565   -0.678589   -0.631885 
     13          1           0        1.266996   -0.132304    1.921281 
     14          1           0        1.450810    0.159310   -2.115469 
     15          1           0        2.843559    0.656151   -1.131192 
     16          1           0        2.371617   -1.059597   -1.199857 
     17          9           0       -0.532877   -0.992168    1.290122 




Total energy of the optimized structure: -1341.3884811 a.u.  
Number of imaginary frequencies: 0   
Cartesian Coordinates: 
--------------------------------------------------------------------- 
 Center     Atomic      Atomic             Coordinates (Angstroms) 
 Number     Number       Type             X           Y           Z 
 --------------------------------------------------------------------- 
      1          6           0       -0.876672    0.827794   -0.849972 
      2          6           0       -0.115227    2.048189   -0.315637 
      3          8           0        1.141722    1.570078    0.190377 
      4          6           0        1.274091    0.147442    0.055444 
      5          6           0       -0.233817   -0.308332   -0.021676 
      6          8           0       -2.256952    1.016500   -0.705973 
      7          8           0        1.977587   -0.350235    1.140766 
      8          6           0        2.091922   -0.199740   -1.186894 
      9         17           0       -0.479660   -1.932688   -0.758034 
     10         17           0       -0.945463   -0.325625    1.649712 
     11          1           0       -0.612550    0.638083   -1.897452 
     12          1           0        0.060976    2.793811   -1.096290 
     13          1           0       -0.684341    2.508196    0.499462 
     14          1           0       -2.717074    0.357745   -1.251672 
     15          1           0        1.516526   -0.067664    1.950986 
     16          1           0        1.594563    0.123510   -2.104211 
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     17          1           0        3.045741    0.328031   -1.104158 




Total energy of the optimized structure: -5564.4136272 a.u.  
Number of imaginary frequencies: 0   
Cartesian Coordinates: 
--------------------------------------------------------------------- 
 Center     Atomic      Atomic             Coordinates (Angstroms) 
 Number     Number       Type             X           Y           Z 
 --------------------------------------------------------------------- 
      1          6           0        0.496505    0.159023    1.583279 
      2          6           0        1.903534    0.715166    1.330244 
      3          8           0        1.832091    1.475733    0.113114 
      4          6           0        0.534509    1.395912   -0.507270 
      5          6           0       -0.048209    0.092521    0.145407 
      6          8           0        0.567144   -1.046699    2.292806 
      7          8           0        0.683035    1.347516   -1.883845 
      8          6           0       -0.271944    2.658254   -0.205234 
      9         35           0       -1.998131   -0.066186    0.082109 
     10         35           0        0.724995   -1.495230   -0.761059 
     11          1           0       -0.116393    0.894783    2.119889 
     12          1           0        2.244833    1.358840    2.145731 
     13          1           0        2.607678   -0.114842    1.205327 
     14          1           0       -0.333929   -1.295045    2.559715 
     15          1           0        1.178054    0.535680   -2.102740 
     16          1           0       -0.435908    2.786110    0.867357 
     17          1           0        0.307893    3.509424   -0.572105 






Chapter 4. 3-Aminooxazolidinone head group-based AHL analogs that 
function as quorum sensing agonists in Gram-negative bacteria 
4.1 Introduction 
The old view that bacteria live in solitary mode has now been replaced with a 
community-based bacterial lifestyle, whereby most bacteria live on surfaces as part of 
polymicrobial biofilms127 and communicate with neighbors using diffusible molecules. 
Bacteria also communicate via contact, using surface associated receptors113b or 
connecting nanotubes.128 Even in the planktonic state, bacteria can still communicate 
with self and non-self neighboring cells and respond to population density via response 
to small molecule autoinducers secreted by other bacteria.19a The cell-to-cell 
communication between bacteria, called quorum sensing (QS), regulates diverse 
phenotypes, including biofilm formation, competence, bioluminescence, virulence 
factors production, antibiotic synthesis.129 Additionally both plant and animal hosts 
respond to bacterial signaling molecules and some QS molecules have been shown 
promote apoptosis or programmed cell death in diverse eukaryotic cell types.130  
In the last decade many small molecules that modulate quorum sensing have 
been developed.9, 88, 131 These QS modulators have been either agonists or antagonists 
and have the potential to be used in diverse applications ranging from inhibition of 
bacterial toxin production and biofilm formation (QS antagonists)132 to manipulation 
of bacterial behavior and synthetic biology applications (both agonists and 
antagonists)133 to the inhibition of cancer (by 3-oxo-C12 HSL 4-1 of Pseudomonas 
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aeruginosa).134 Thus far acylhomoserine lactone (AHL)-based QS modulators have 
been the most rigorously pursued by many groups. The majority of these compounds 
have targeted LasR from P. aeruginosa.9-15  
Most of the AHL analogs developed to date have kept the acylhomoserine 
lactone headgroup and modified the acyl chain. A few lactone head group modifications 
have also been reported but often, modification of the head group usually lead to 
dramatic reduction of activity.90b  Unfortunately γ-lactones are not chemically stable 
and can hydrolyze in mild acidic or basic environments.135 Additionally bacterial, plant 
or animal lactonases136 and acylases137 have been shown to readily inactivate AHLs so 
there is clearly a need for an AHL head group that is resistant to hydrolysis and at the 
same time maintains the high QS modulatory activity seen with homoserine lactones.  
We docked several lactone mimics into the active site of P. aeruginosa LasR 
and found that oxazolidinone-based AHL analogs had similar conformation in the 
binding site of LasR as the native 3-oxo-C12-HSL 4-1. The docking results were 
surprising to us because many reports have documented the importance of the chirality 
at the C3 position for AHL autoinducers in activating QS-mediated processes.92b, 131b, 
138 In this report we show that these 3-aminooxazolidinone analogs that lack C3 
chirality still bind to LuxR-type receptors and are potent in binding to LasR as the 
native 3-oxo-C12 HSL 4-1. As an added advantage, the 3-aminooxazolidinone head 
group is more resistant to hydrolysis than AHLs and are therefore good replacements 
for the lactone head group in AHL-based QS modulators. These analogs (Figure 4-1) 
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can be made from inexpensive materials in a few steps and are drug-like (examples of 
oxazolidinone drugs are linezolid139 and rivaroxaban140).   
 
 
Figure 4-1. Structures of oxazolidin AHL analogs compared with natural AI-1. 
 
4.2 Results and Discussion 
3-oxo-HSLs are known to degrade under weakly basic conditions and 
tautomerize to a tetramic acid derivative via a mechanism shown in Scheme 4-1.135 To 
demonstrate that our 3-aminooxazolidinone-based analogs are superior to natural 
AHLs in terms of chemical stability, we monitored the degradation 3-oxo-C12-HSL 4-
1 and 3-oxo-C12-3-aminooxazolidinone 4-3, at pH = 8.0 by monitoring UV absorption 
at 278 nm, which is an absorption maxima for tetramic acid, as a function of time 
(Figure 4-2). Whereas the UV absorption for the 3-oxo-C12-HSL 4-1 incubation 
increased over time, that of the analog 4-3 remained stable over 3 h. TLC analysis also 
revealed that analog 4-3 remained intact after 3 h after incubation in Tris buffer (pH = 
8.0), see Figure 4-3. We therefore concluded that 3-aminooxazolidinone analog 4-3 is 




Scheme 4-1. Degradation of AHL under basic condition. 
Recently Raines revealed that the conformation of free AHLs is different from 
when complexed to LasR. In the free state, the lone pairs of the amide carbonyl forms 
a favorable interaction with the π* of the lactone carbonyl.141  This n to π* interaction 
(worth about 0.64 kcal/mol), is disrupted upon binding to LasR. Interestingly the 
substitution of the C3 in 3-oxo-C12-HSL 4-1 with N3 (aminooxazolidinone-based 
analogs) did not abrogate the n to π* interaction in the free state (see Figure 4-4). Also 
the C3 to N3 substitution did not drastically change the surface charge potentials of the 
head group moieties (see compare compounds C2-HSL 4-5 and C2-3-
aminooxazolidinone 4-6 in Figure 4-4), implying that our analogs would be able to 





Figure 4-2. Stability studies of 3-oxo-C12-HSL 4-1 and 3-oxo-C12-3-
aminooxazolidinone 4-3. (Done by Yue Zheng, a graduate student in the Sintim group). 
 
Figure 4-3. Stability studies of 3-oxo-C12-3-aminooxazolidinone 4-3 monitored by 




Figure 4-4. Surface charge potential on simplified models of AHL and oxazolidinone 
based mimic. n→π* interactions from one lone pair (n) of the acyl carbonyl group 
oxygen to the empty π* on the carbon of carbonyl group in the lactone ring and the 
distances are highlighted. Computational level: B3LYP/6-311+G(d,2p).121 
 
 
Figure 4-5. The binding domain (green) in crystal structure of LasR (PDB code: 2UV0) 
with native 3-oxo-C12-HSL 4-1 (cyan) and re-docked analog 4-3 (yellow). 
 
In most LuxR-type proteins reported to date, Trp60 is highly conserved.142 Both 
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Suga and Blackwell have shown that this residue determines whether a ligand acts as 
an agonist or antagonist.143 Ligands that exhibit unfavorable interactions with Trp60 
have antagonistic profiles. Recently Blackwell also revealed that the interactions 
between a ligand and Tyr56 and Ser129 in LasR are also important in determining 
whether a ligand acts as an antagonist or agonist since these residues bond to the 
carbonyl of the 3-oxo-C12-HSL 4-1 ligand to position the lactone head group towards 
Tyr 60, which is a key residue.143a, 144  Docking experiments145 revealed that the 
docked pose of 3-oxo-C12-HSL 4-1 and 3-aminooxazolidinone analog 4-3 are similar, 
with the exception of the orientation of the 3-oxo group, see Figure 4-5. Importantly, 
the carbonyl head group of both the native ligand and the 3-aminooxazolidinone analog 
4-3 are similarly oriented towards the key Trp60 residue, hinting that 3-
aminooxazolidinone analog 4-3 would also act as an agonist. 
To test whether 3-aminooxazolidinone analog 4-3 would function similarly as 
native 3-oxo-C12-HSL 4-1, as predicted by the docking experiment (see Figure 4-5), 
we used bacterial reporter strain E. coli pSB1075 (lasRI’::luxCDABE) to test for 
agonsim. In the presence of native 3-oxo-C12-HSL 4-1 (10 nM), this bacterial strain 
produced bioluminescence as expected, see Figure 4-6. Similarly, 3-
aminooxazolidinone analog 4-3 (10 nM), could also induce bioluminescence in E. coli 
pSB1075 and the bioluminescence intensities induced by both the native 3-oxo-C12-





Figure 4-6. Biolumninescence production induced by native 3-oxo-C12-HSL 4-1 (10 
nM orange) and 3-oxo-C12-3-aminooxazolidinone 4-3 (10 nM, blue) in E. coli 
pSB1075. (With the help of Yue Zheng, a graduate student in the Sintim group). 
Next, we investigated if other LuxR-type proteins would also respond to 
oxazolidinone analogs. Chromobacterium violaceum CV026 is a biosensor strain that 
does not produce its own AI-1 but can respond to C4 to C8 AHL molecules, via binding 
to its LuxR type QS system CviR, to produce violacein.146 However, long chain AHLs 
such as 3-oxo-C12-HSL can inhibit the C4-C8 AHL-induced production of 
violacein.146 Addition of 20 μM of C4-HSL 4-2 to agar or liquid culture incubated with 
CV026 led to the production of a violet pigment (Figure 4-7a and 4-8). C4-3-
aminooxazolidinone 4-4 was also able to induce the purple colonies, but unlike LasR, 
CviR preferred the native C4 HSL 4-2 to C4-3-aminooxazolidinone 4-4 as a higher 
concentration of analog 4-4 (200 µM, compare Figure 4-7b with Figure 4-7a that used 
20 µM of C4-HSL 4-2) was needed to give the same degree of pigmentation. 
















in CV026 in both agar and liquid cultures, see Figures 4-7c and 4-8. The 3-oxo-C12-
3-aminooxazolidinone 4-3, could also inhibit C4-HSL 4-2 induced violacein 
production in CV026, but here too the concentration of 3-aminooxazolidinone analog 
4-3 needed to inhibit the activity of 20 mM C4-HSL 4-2 was higher than the natural 3-
oxo-C12-HSL 4-1 ligand (see Figures 4-7d and Figure 4-8).  
 
Figure 4-7. Chromobacterium violaceum CV026 agar assay. a) and b): cultured with 
different concentrations of C4-HSL 4-2 and analog 4-4. c) and d): cultured with 
different concentrations of 3-oxo-C12-HSL 4-1 and analog 4-3 in presence of C4-HSL 





Figure 4-8. Chromobacterium violaceum CV026 liquid broth assay with various 
additives. (Done by Yue Zheng, a graduate student in the Sintim group) 
4.3 Conclusion. 
In the past decade intensive efforts have been dedicated to the discovery of QS 
agonists and inhibitors. QS autoinducers have been shown to activate the immune 
system and hence these molecules and more stable analogs thereof have the potential 
to be used in cancer immunotherapy.134 Hence hydrolytically stable 3-oxo-C12-HSL 
analog 4-3 described in this manuscript could have anticancer properties and future 
works along this line are planned. AI-1-based agonists also have the potential to be 
used in synthetic biology applications whereby genetic circuits that are regulated by 










agonists described in this paper, which are more stable towards chemical degradation 
than the natural autoinducer, could become useful in these applications. LasR receptors 
could accommodate the C3 to N3 substitution better than CviR protein. LasR is key to 
the production of various virulence factors during P. aeruginosa infection and future 
work will focus on making side chain variants of the oxazolidinone analogs and test for 
activity against P. aeruginosa. 
4.4 Detailed experimental procedures and characterizations 















Scheme 4-2. Synthesis of oxazolidin analogs. 
 
The starting material 4-7 is commercially available. It is however expensive but can be 
prepared on gram scale as follows: To a mixture of 2-hydroxylethylhydrazine (2.3g, 30 
mmol) and dimethyl carbonate (4.0 mL, 48 mmol) was added a solution of NaOH (0.1g, 
2.5 mmol) in 0.5 mL methanol. The resulting mixture was heated and stirred at 70 °C 
for 3 h. Then the reaction was cooled down to room temperature and the unreacted 
dimethyl carbonate was removed in vacuo. The residue was purified by silica column 
chromatography (methanol: dichloromethane = 1: 30, v/v) to afford 4-7 as a white solid 
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(2.01 g, 65%).  
  
Compound 4-2 was synthesized according to literature procedure.148 
  
To a solution of 4-8 (50 mg, 0.19 mmol) in anhydrous dichloromethane was added 
oxalyl chloride (40 µL, 2.3 equiv) at room temperature. The mixture was allowed to 
stir for 5 h. Then the reaction was concentrated to remove solvent and excess oxalyl 
chloride. The residue was re-subjected to dry dichloromethane and the resulting 
solution was added slowly to a solution of 4-7 (39 mg, 2 equiv) in dry dichloromethane 
at 0 oC. The mixture was allowed to slowly warm up to room temperature and stirred 
overnight. Then the reaction was concentrated under vacuum, and the residue was 
purified by silica column chromatography (methanol: dichloromethane = 1: 40, v/v) to 
afford 4-9 as a white solid (59 mg, 90% yield).1H NMR (CDCl3, 400 MHz) δ 8.39 (s, 
1H), 4.41 (t, J = 7.8 Hz, 2H), 4.11-4.02 (m, 2H), 4.02-3.93 (m, 2H), 3.81 (t, J = 7.8 Hz, 
2H), 2.65 (s, 2H), 1.78-1.67 (m, 2H), 1.44-1.32 (m, 2H), 1.32-1.18 (m, 12H), 0.87 (t, J 
= 6.8 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 168.8, 157.8, 109.8, 65.6, 62.3, 46.3, 
43.5, 38.0, 32.3, 30.1, 29.9, 29.7, 24.0, 23.1, 14.5; HRMS (ESI-TOF) m/z calcd. for 




Compound 4-9 (55 mg, 0.16 mmol) was dissolved in trifluoroacetic acid (0.64 ml) and 
water (0.16 ml). The mixture was stirred at room temperature overnight. Then the 
reaction was quenched by saturated NaHCO3 (aq) until the solution turned neutral. 
Dichloromethane was used to extract the product three times and the organic phase was 
dried with anhydrous MgSO4. The product was purified by silica column 
chromatography (methanol: dichloromethane = 1: 40, v/v) and afforded 4-3 as a white 
solid (34 mg, 71% yield). 1H NMR (CDCl3, 400 MHz) δ 9.08 (s, 1H), 4.44 (t, J = 7.8 
Hz, 2H), 3.84 (t, J = 7.8 Hz, 2H), 3.52 (s, 2H), 2.56 (t, J = 7.4 Hz, 2H), 1.64-1.52 (m, 
2H), 1.35-1.18 (m, 12H), 0.88 (t, J = 6.8 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 205.8, 
165.9, 158.0, 62.5, 48.0, 46.4, 44.1, 32.2, 29.8, 29.6, 29.4, 23.1, 14.5; HRMS (ESI-
TOF) m/z calcd. for C15H27N2O4 [M+1]+ 299.1971, found 299.1967. 
 
To a solution of 4-7 (102 mg, 1 mmol, 2 equiv) in anhydrous dichloromethane was 
added butyryl chloride (50 µL, 0.5 mmol, 1 equiv) at 0oC. The mixture was allowed to 
warm up to room temperature slowly and stir for 3 h. Then the reaction was 
concentrated under vacuum, and the residue was purified by silica column 
chromatography (methanol: dichloromethane = 1: 30, v/v) and afforded 4-4 as 34 mg 
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pale yellow oil (40% yield).1H NMR (CDCl3, 400 MHz) δ 8.49 (brs, 1H), 4.45 (t, J = 
8.1 Hz, 2H), 3.84 (t, J = 8.1 Hz, 2H), 2.23 (t, J = 7.4 Hz, 2H), 1.78-1.61 (m, 2H), 0.98 
(t, , J = 7.4 Hz, 3H),; 13C NMR (CDCl3, 100 MHz) δ 172.9, 158.5, 62.5, 46.4, 36.0, 
19.0, 14.0; HRMS (ESI-TOF) m/z calcd. for C7H13N2O3 [M+1]+ 173.0926, found 
173.0903. 
Docking calculations: 
Docking calculations were performed using Autodock Vina 1.1.1.145a A large grid box, 
which is enough to encompass the ligand in the binding pocket was chosen. The 
exhaustiveness value was set as 32 in the Autodock calculations and the rest of the 
parameters were used as default. The ligand PDB files were prepared with ChemDraw. 
Autodock Tools 1.5.4 was used to convert the PDB files into PDBPT files for the 
Autodock vina calculations. The top-ranked conformation poses were selected for 
analysis. Results were visualized using PyMOL viewer version 1.3.145b 
Stability studies: 
Stability of 3-oxo-C12-HSL 4-1 and 3-oxo-C12-3-aminooxazolidinone 4-3 towards 
basic pH was determined via UV monitoring.109, 135 Briefly, the decomposition of AI-1 
or analog (1 mM) in 180 mM Tris-HCl, pH 8.0 at 25 °C was monitored by following 
absorbance changes at 278 nm, using Jasco V-630 Spectrophotometer for 3 hours. 
(Done by Yue Zheng, a graduate student in the Sintim group). 
Stability of 3-oxo-C12-3-aminooxazolidinone 4-3 towards basic pH was determined 
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via TLC, as well (Figure S1). 10 mM of analog 4-3 in methanol was mixed with 
equivolume of 250 mM Tris-HCl buffer (pH = 8.0) and left at 25 °C for 3 hours. The 
mixture along with analog 4-3 stock solution and Tris-HCl buffer were spotted on TLC 
plate and developed using eluent (methanol: dichloromethane = 1: 40, v/v). After 
developing, the TLC plate was air dried and stained by KMnO4 solution. 
Bioluminescence assay: 
E. coli JM109 (pSB1075) (containing luxRI::luxCDABE, bioluminescent reporter,) 
was cultured at 37 °C overnight and diluted 10 times with fresh medium. After culture 
at 37 °C for 7 hours, OD600 was measured and diluted to OD600=0.01. Cell culture was 
grown in 37 °C for another hour and diluted to OD600=0.005. Different concentrations 
of AI-1 and analogs were added to cells and incubated at 37 °C with shaking for 8 hours. 
Bioluminescence was measured with a Nichols Institute Diagnostics luminometer. 
C. violaceum CV026 AHL reporter assay:  
Agar plate assay:149 Different concentration of AI-1 and analogs were added into LB 
agar. C. violaceum CV026 was stretched onto the agar plates. Plates were incubated at 
37 °C for one day and 25 °C for another 2 days.  
Extraction and quantification of violacein:150 C. violaceum CV026 overnight culture 
was diluted to OD600=0.1 and mixed with AI-1 or analog. After incubation at 27 °C for 
60 hours, 1 ml of bacteria culture was centrifuged at 14000 rpm for 5 min. Supernatant 
was removed and pellet was resuspended in 1 ml DMSO. Cells were removed by 
centrifugation and OD585 was measured by Molecular devices SpectraMax M5e 
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microplate reader. (Done by Yue Zheng, a graduate student in the Sintim group). 
Gaussian calculations: 
All the structures interested were optimized at B3LYP/6-311+G(d,2p) level using 
Gaussian 09.121  
 
Total energy of the optimized structure: -530.6919083 a.u.  




 Center     Atomic      Atomic             Coordinates (Angstroms) 
 Number     Number       Type             X           Y           Z 
 --------------------------------------------------------------------- 
      1          8           0       -2.207400    0.597804    0.417294 
      2          6           0       -2.488988   -0.789922    0.126249 
      3          6           0       -1.135221   -1.405660   -0.243829 
      4          7           0       -0.426173   -0.199802   -0.663400 
      5          6           0       -0.986195    0.933748   -0.067118 
      6          8           0       -0.509517    2.030586   -0.019531 
      7          7           0        0.938859   -0.227980   -0.868638 
      8          6           0        1.806973   -0.233053    0.212484 
      9          6           0        3.253739    0.026629   -0.139456 
     10          8           0        1.418354   -0.456282    1.338508 
     11          1           0       -2.938874   -1.233962    1.011189 
     12          1           0       -3.197045   -0.822955   -0.703787 
     13          1           0       -1.215010   -2.123624   -1.060265 
     14          1           0       -0.641145   -1.869584    0.612245 
     15          1           0        1.241964    0.170495   -1.744742 
     16          1           0        3.463705   -0.079523   -1.204685 
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     17          1           0        3.501542    1.045191    0.167576 
     18          1           0        3.882720   -0.658875    0.426597 
 --------------------------------------------------------------------- 
 
Total energy of the optimized structure: -514.6702856 a.u.  
Number of imaginary frequencies: 0   
Cartesian Coordinates: 
--------------------------------------------------------------------- 
 Center     Atomic      Atomic             Coordinates (Angstroms) 
 Number     Number       Type             X           Y           Z 
 --------------------------------------------------------------------- 
      1          8           0        2.134690    0.578829   -0.515899 
      2          6           0        2.415670   -0.823569   -0.282464 
      3          6           0        1.119685   -1.442440    0.254461 
      4          6           0        0.421095   -0.234184    0.887613 
      5          6           0        1.001203    0.962826    0.109672 
      6          8           0        0.575851    2.079839    0.082757 
      7          7           0       -1.024813   -0.253123    0.923912 
      8          6           0       -1.777717   -0.220358   -0.223210 
      9          6           0       -3.262048    0.005887   -0.029387 
     10          8           0       -1.277448   -0.368928   -1.324122 
     11          1           0        2.740697   -1.248342   -1.229975 
     12          1           0        3.237967   -0.880390    0.434742 
     13          1           0        1.312689   -2.244081    0.967066 
     14          1           0        0.511857   -1.825909   -0.561280 
     15          1           0        0.760761   -0.105998    1.919653 
     16          1           0       -1.465837    0.048584    1.777201 
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     17          1           0       -3.594605   -0.155548    0.997147 
     18          1           0       -3.492810    1.034358   -0.316175 








Chapter 5. Conclusions. 
5.1 AI-2 mediated quorum sensing inhibitors. 
In this dissertation, we have shown that small molecules that are based on 
natural QS autoinducers can be used to modulate quorum sensing. Others83b, 84a, 87, 107a, 
108, 117 and us83a, 84c, d have proven that minor chemical changes (Figure 6-1) on the 
ubiquitous universal bacterial signaling molecule AI-2 can impact the agonist or 
antagonistic profile of the analog.  
 
Figure 5-1. Chemical modification sites on AI-2. 
Thus far, AI-2 analogs with different alkyl groups on C1 position, including 
linear, branched and cyclic alkyl chains as well as aromatic rings have been made and 
tested for QS activity. In the majority of cases, C1 alkyl analogs of AI-2 were 
antagonists.83, 84c, d We have replaced the 3’3’-hydroxyl groups with germinal halogens 
at C3 position and shown that these are active QS modulators (agonists or antagonists, 
depending on the nature of C1 substituent). C5 alkyl analogs of AI-2 have also been 
reported and these compounds exhibit agonistic behavior to some extent depending on 
the nature of the substituent.87 The group of Gardiner, et al. replaced the C4 hydroxyl 
group of AI-2 and the C4-fluoro analog exhibited antagonist activity.117 Stable analogs 
of AI-2, which can be readily purified on column chromatography, have also been 
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reported by others and us. These stable analogs are ester protected compounds 
(hydroxyl groups at C4 and C5 were protected) can be deprotected in vivo by cellular 
esterases to yield the active compounds.85-86, 107a Janda has also reported carbocyclic 
analogs of AI-2 but these analogs were not potent QS modulators.110 The majority of 
AI-2 analogs reported to date have been tested on only V. harveyi or E. coli/Salmonella. 
However AI-2 signaling has been observed in many bacetria (see Table X). In future 
these compounds could be investigated for their QS modulation in other bacteria that 




5.2 AI-1 mediated quorum sensing inhibitors. 
AI-1 in Gram-negative bacteria regulates many processed and analogs thereof 
have been intensively studied in the past three decades and most of them were based 
on N-acyl homoserine lactone (AHL) head group. In this dissertation, we presented a 
very promising head group, 3-aminooxazolidinone, which has remained largely 
unexplored. We proved that this head group was superior to the native AHL in terms 
of chemical stability and also retained similar activities as the native one. Hence it is a 
good platform/structure to develop drug-like QS inhibitors. Future work in the Sintim 
group will focus on the synthesis of 3-aminooxazolidinone libraries to discover new 
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